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Patient self-management technologies (glucometer, blood pressure monitor, 
etc.) are a critical component of chronic disease care. Although these technologies are 
intended to support patient activities, low device usability can produce design imped-
iments that may negatively impact patient adherence and hence treatment outcomes. 
In particular, patients with disabilities, who are the majority of the chronic disease 
population, are typically excluded from medical device usability studies required for 
FDA approval. This study aims to develop a usability method to: 1) evaluate patient 
self-management technology and 2) inform design decision making for disabled pa-
tients. The study will focus on handheld device use (glucometers) for diabetic patients 
with mobility and vision impairment. An initial expert usability analysis was per-
formed for 13 glucometers to determine the design features that are most problematic 
for disabled users. The usability analysis informed the design of an experiment to test 
disabled user performance and satisfaction for several meter interaction tasks. Com-
  
mon diabetes disabilities were simulated in healthy subjects through the use of glasses 
(retinopathy, glaucoma) and gloves (arthritis, neuropathy) to evaluate the experi-
mental protocol prior to future testing in the actual disease population. Results sug-
gested a preference of participants for large text, large protruding buttons, and con-
trast color between case and buttons to facilitate locating buttons. Future studies will 
integrate the disabled diabetic population in the data collection and integration of 
these results in the design of a new glucometer.  This work can inform regulatory 
guidelines for usability testing with disabled patients and the patient-centric design 
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After my arrival to the United States in 2012, I was introduced to usability as a means 
to design products that meet end-users needs. Usability is critical in situations where 
products are used by a diverse population, in particular chronic disease management 
devices such as glucometers. Indicative of the importance of usability, the Food and 
Drug Administration (FDA) now requires usability testing for certain medical devic-
es, specifically the highest risk devices that go through the most stringent approval 
process (Pre-Market Approval). I become more familiar with the FDA’s role in usa-
bility testing through interactions with the FDA Human Performance Lab, where re-
search is performed on a variety of device concerns, including functional glucometer 
testing. It was through this interaction and further research into the regulatory design 
requirements for disabled individuals (i.e., Americans with Disabilities Act) that I 
found several loopholes that make it possible to design a medical device that does not 
meet the needs of an entire subpopulation of users.  Thus, I was motivated to address 





This study focuses on identifying device features that better support glucometer usa-
bility for users with mobility or visual limitations. This is not only of interest to me-
chanical engineering but also of interest to other fields—bioengineering, sociology, 
psychology, and public health. This research has far reaching implications and can 
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Chapter 1: Introduction 
Patient self-management and treatment adherence, particularly for chronic 
conditions, has been shown to be associated with improvements in health status and 
decreased utilization of medical services (Asche, LaFleur, & Conner, 2011; Lorig et 
al., 1999). Patient self-management technologies are a critical component of chronic 
disease care and empowers patients to actively participate in their treatment. These 
technologies facilitate regular collection of health vitals (blood glucose, blood pres-
sure, etc.) and diagnosis of current health state. Self-management technologies en-
compass not only biomedical mobile devices that can continuously monitor the pa-
tients' health status, but also wired and wireless communication devices and telemed-
icine servers to collect data on the patients’ health status (Lee, Chen, Hsiao, & Tseng, 
2007). This process improves treatment communication in transitions from the 
healthcare provider to a home setting (Coleman & Berenson, 2004) by communi-
cating health status updates to the medical personnel and aiding in coordination of 
care across transitions in care settings.  
1.1 Usability 
Poor device usability compromises successful self-management technology 
use. Usability is an attribute that characterizes ease of device learnability and usage 
by a range of users and implements methods to measure and improve ease-of-use 
(Lin, Choong, & Salvendy, 1997). There are significant cognitive and usability barri-
ers for patient interaction with self-management technologies. Small screens and 




ticularly older adults and users with disabilities who represent a considerable segment 
of the chronic disease patient population (Lai, Kaufman, Starren, & Shea, 2009). A 
large percentage of chronic disease patients have vision (i.e., retinopathy, glaucoma, 
cataracts) and mobility impairment (i.e., neuropathy, amputation). In addition chronic 
disease patients tend to have lower health literacy and socio-economic status (SES), 
which may negatively impact their perceived device usability and adherence to rec-
ommended device use. Failure to match patients to a suitable device can lead to im-
proper use, non-adherence to instructions, and poor outcomes. 
1.2 Diabetes 
Diabetes is a highly prevalent chronic condition with high rates of patient non-
adherence due to the disease complexity (multiple providers and treatment regimens) 
and longevity. According to Harris (2001), more than one quarter of diabetes Type II 
patients had never monitored their blood glucose level or have done it less than once 
per month. The current number of diagnosed diabetes cases in the United States is es-
timated to be 25.8 million—8.3 % of the population—with seven million undiag-
nosed cases (Centers for Disease Control and Prevention (CDC), 2011). Diabetes is 
also a leading cause for several other chronic diseases—namely atherosclerotic vascu-
lar disease, renal failure, vision impairment, and lower extremity amputation (CDC, 
2011). Diabetes complications include a variety of vision and mobility impairments 
that may impair proper device use. 
About 28% of diabetics aged 40 years or older have diabetic retinopathy and 
are 40% more likely to suffer from glaucoma compared to people without diabetes 




system damage that affects about 60% to 70% of diabetics. As a result diabetics have 
mild to severe nervous system damage including impairment sensation or hand pain 
(CDC, 2011).  
1.3 Diabetes as a Disability 
The American with Disabilities Act Amendments of 2008 (“ADAA”) estab-
lish diabetes as a disability under the American with Disabilities Act if the condition 
substantially limits a major life activity (i.e., vision and mobility impairment due to 
diabetes compilations). Despite this, manufacturers are not required by law to design 
glucometers to accommodate diabetic patients with disabilities. Some handheld medi-
cal devices have been made accessible to those with a disability, but they are not as 
common. For example, for blind users, several technologies exist: Prodigy Voice® 
from Prodigy®; and Diabetes Care and Solus V2 from BioSense Medical Devices. 
Manufacturers are also required by the Food and Drug Administration (FDA) to 
demonstrate the application of human factors engineering to the design of medical 
devices through required usability testing. However, most usability tests are conduct-
ed with healthy subjects whose needs clearly differ from those of disabled patients, 
who are the majority of the glucometer user population. 
1.4 Objectives 
This research addresses the aforementioned issues by empirically evaluating 
hardware and software modular components (screen, button, casing, etc.) of glucome-
ters to guide the device design process and the development of generalized handheld 




phases: 1) Perform an expert heuristic usability evaluating of existing glucometers to 
determine the most influential design features for users with disabilities; and 2) Per-
form user testing of the critical features identified in Phase 1 through the simulation 
of vision and mobility impairment in healthy subjects. The disability simulation study 
in Phase 2 serves as a pilot of the experimental protocol and provides a foundation to 
test the design features in the actual target population (disabled diabetes patients) in a 
future study. The results of this research can potentially inform medical device manu-







Chapter 2:   Background 
This chapter provides an overview of disability regulations, diabetes, and 
handheld design guidelines. First, handheld device design guidelines currently availa-
ble are introduced along with FDA human factors requirements for medical devices. 
Next, regulations advocating for disabled persons in the Unites Stated and its rela-
tionship with diabetes is discussed. Finally, an overview of diabetes is presented. 
2.1 Handheld Device Design Guidelines 
Despite the increase popularity of handheld devices, no design guidelines tai-
lored for disabled persons are available. A few guidelines for handheld designs are 
publicly accessible, however, they are not detailed enough to provide dimensions of 
buttons, screen, and casing. These features, discussed later in the document (Section 
4.1), are influential in the perceived usability of devices, particularly for persons with 
visibility and mobility limitations.   
2.1.1 Department of Defense Guidelines 
The Department of Defense (DoD)  developed a handbook that provides basic 
guidelines on human engineering design for military systems, equipment, and facili-
ties (DoD, 1995). Most of the recommendations presented are not directly applicable 
to handheld devices or to disabled persons. However, human factors implementation 
throughout the development of the guidelines makes the handbook a popular refer-




In the DoD handbook, push buttons, the most common type of input in 
handheld medical devices, are discussed in more detail compared to screens and cas-
ing. Very little reference is made to case design. Guidelines for push buttons are 
summarized in Figure 2, which includes dimensions, spacing, and general recom-
mendations. Screens, the communication medium between the device and the user, 
are largely discussed in different applications. However, the handbook focuses on 
scale graduation pointers and cathode ray tube displays. In the case of small applica-
tions, the handbook provides general guidelines which include: only displaying in-
formation that is essential; segment display (non-continuous display formed with sev-
en bars, see Figure 1) is acceptable for numerals only; and light symbols on a dark 
background should be used when work area illumination is low. 
Outside of defense, other industries have discussed the importance of human 
factors in product design, such as aviation.  
 
Figure 1: Seven-Segment Display (Perm, 2009) 
2.1.2 Federal Aviation Administration 
The Federal Aviation Administration (FAA) asked Zingale, Ahlstrom, and 
Kudrick (2005) to identify the advantages and disadvantages of handheld, portable, 









Although the document is a detailed description of Personal Digital Assistant 
(PDA), Smart Phones, Blackberrys®, and Tablet Computers (commonly known 
simply as tablets), it also includes general human factors considerations for handheld 
devices which include: 
• Equipment should have a non-slip surface and be shaped so as to pre-
vent it from slipping out of the user’s hand.  
• The display should accommodate expected operational lighting condi-
tions, both high and low illumination. 
• Portable equipment should have rounded corners and edges. 
• Device weight should not be more than 5.1 lb. (2.3 kg). 
• Device should be smaller than 4”x10”x5”. 
The FAA provides general design guidelines that are applicable to handheld 
medical device design but does not explore features as buttons, screen, and casing. 
The medical industry has also shown interest in the application of human factors dur-
ing the design process.  
2.1.3 Association for the Advancement of Medical Instrumentation  
The Association for the Advancement of Medical Instrumentation (ANSI, 
AAMI, 1993) developed guidelines for the design of medical devices. The AAMI 
document focuses on controls, displays, consoles, and general user interface design of 
medical devices; however the recommendations are not specific for handheld applica-
tions. Nevertheless, general dimensions for push buttons are provided by the authors 




In addition to AAMI, FDA has also developed human factors guideless and 
regulations for medical devices. 
 




2.2 FDA Usability Testing 
FDA requires manufacturers to include usability testing data as part of Pre-
Market Approval (PMA) and 510k submissions. This requirement is intended to im-
prove usability of medical devices and minimize human errors. Manufacturers must 
demonstrate implementation of human factors during device development by submit-
ting pertinent documentation. Three specific design requirements must be met. 
• Design Input: ensure device design requirements are in accordance 
with the intended use of the device as well as with the end-user needs.  
• Design verification: assure device design meet design input require-
ments. The process shall be documented in a design history file. 
• Design validation: manufactures must validate the device design by 
comparing it to the design input requirements in addition to test it un-
der actual or simulated use conditions. 
Specifically, FDA recommends the use of analytical methods and formative 
evaluations to analyze and understand use-related hazard in the design process (FDA, 
2011).  
Analytical methods constitute describing and systematic decomposing a de-
vice. Among these methods are: Task Analysis, a method requiring decomposing de-
vice use process into elemental tasks; and Heuristic Evaluation, a process in which 
evaluators analyze a device user interface against well-established design rules (FDA, 
2011). Both techniques are applied in this study and are discussed in more detailed in 
Section 3.1. Formative evaluations involve user interaction with the device under dif-




errors. Two methods are presented by the FDA: cognitive walk-through, which in-
volves users verbalizing their thoughts while performing certain tasks; and user test-
ing, data collection from users while interacting with a device in realistic situations. 
User testing is incorporated in this study as described in Section 3.2. 
Although FDA provides detail on the types of usability tests that should be 
performed for approval submission, requirements for subpopulation inclusion is miss-
ing and vulnerable populations are frequently overlooked. Therefore, several glu-
cometers have low usability for individuals with visual or mobility impairments. Per-
tinent regulations requiring the accommodation of products and services for individu-
als with disability is discussed in the next section.  
2.3 Disability Regulations 
In 1990, President George W. Bush signed the Americans with Disabilities 
Act (ADA) into law, which prohibits discrimination against people with disabilities. 
On January 1, 2009, the Americans with Disabilities Act Amendments Act (ADAAA) 
of 2008 went into effect primarily to broaden the definition of disability (Job 
Accommodation Network, 2013) since previous definitions made protection under 
ADA unattainable. 
Instead of limiting disability to a list of impairments, ADAAA defines a per-
son with disability as an individual who meets one of the following criteria: 
• Have a physical or mental impairment that substantially limits one or 
more major life activities of such individual. 
• Have a record of such impairment. 




Nevertheless, the Law provides a list of impairment that, under virtually all 
circumstances, will ratify an individual as disabled. The list, found in 29 C.F.R. § 
1630.2(j) (3), includes deafness, blindness, autism, cancer, and diabetes, among oth-
ers conditions. Diabetes is considered a disability and diabetic individuals are entitled 
to receive protection under ADAAA. 
The Act is divided into five titles that cover major areas of everyday life (Civil 
Rights Division, 2009; Job Accommodation Network, 2013):  
• Title I: Employment: prohibits discrimination in any aspect of em-
ployment based on disability status.  
• Title II: Public Services: prohibits public entities to deny services to 
people with disabilities or deny participation in programs or activities 
that are available to people without disabilities.  
• Title III: Public Accommodations: requires that all new construction 
and modifications of public and commercial facilities must be accessi-
ble to individuals with disabilities. 
• Title IV: Telecommunications: amends the Telecommunications Act 
of 1996 requiring manufacturers and providers of telecommunications 
to ensure products and services are accessible to individual with disa-
bilities. 
• Title V: Miscellaneous Provisions: includes a provision prohibiting 
coercing or retaliating against individuals with disabilities or persons 





Although Title I and II specifically address accessibility to services and public 
accommodations, technology design is omitted.  Title IV is the only act that refer-
ences technology; however, this restricted to telecommunications technology and 
does not include medical devices. These loopholes allow medical device manufactur-
ers to develop and get regulatory approval for products that are not accessible and do 
not accommodate disabled user, in particular diabetic patients who have to rely on 
glucometers to manage their disease. 
2.4 Diabetes 
Diabetes is chronic disease involving high or low levels of blood glucose. 
During digestion, carbohydrates are broken down into glucose, a form of sugar that is 
a source of fuel for the body. Glucose is moved by insulin—a hormone produced by 
the pancreas—from the bloodstream to cells throughout the body. Diabetes develops 
when the body is not able to produce enough insulin or is incapable to use insulin ef-
fectively, or both (National Diabetes Information Clearinghouse, 2008). 
Two mayor types of diabetes exist: Type I, predominantly diagnosed to young 
individual with insulin deficiency due to the destruction of cells in the pancreas; and 
Type II, the most common form of diabetes consisting largely of adults with insulin 
resistance (National Diabetes Information Clearinghouse, 2011). Also it is possible 
for women to develop gestational diabetes during pregnancy although this type of di-
abetes is less common. 
In the United States alone, the Center for Disease Control and Prevention 
(CDC) (2011) estimated that 8.3% of the population—25.8 million people—has been 




sented the largest group of diabetics (Figure 4). This is particularly important since 
older individuals tend to have more diabetes complications and disabilities resulting 
from those complications as a result of the longevity of their diabetes.  
 
Figure 4: Estimated percentage of people aged 20 years or older with diagnosed and undiagnosed dia-
betes in the United States, 2005-2008 (CDC, 2011) 
In addition, diabetes poses a significant cost to patients and the healthcare sys-
tem. CDC (2011) has estimated this cost to the healthcare system as $174 billion in 
the United States. Diabetics also have double the medical expenditures compared 
with non-diabetic patients, mainly due to multiple additional complications (CDC, 
2011).  
Diabetes increases the risk of health complications (vision and mobility im-
pairment) that may negatively impact self-management technology usage, particularly 
for handheld devices which require manual grasping, button pressing and reading in-
formation on small screens. Common complications affect vision and mobility of pa-
tients.  Among regular eye illness are glaucoma, cataracts, and diabetes retinopathy. 




(National Eye Institute, n.d.). This disease is 40% more likely to affect diabetics than 
non-diabetics (American Diabetes Association, 2013b). Similarly, cataracts, an eye 
disease caused by clouding of the lens in the eye (National Eye Institute, 2009), are 
60% more likely to be developed by people with diabetes, compared with non-
diabetics. Diabetes retinopathy, a family of eye diseases involving blurred vision with 
floaters, has been diagnosed to 4.2 million (28.5%) people with diabetes aged 40 
years (CDC, 2011).  
Nerve damage, widely known as diabetes neuropathy, is another health prob-
lem found in about 60% of the diabetes population (CDC, 2011). Consequences in-
clude impaired sensation or pain in the feet or hands, slowed digestion of food, carpal 
tunnel syndrome, and even amputation. Similar mobility impairment effects are 
caused by arthritis, one of the most prevalent diseases in the United States affecting 
22.7% of the adult population (CDC, 2013). In addition, arthritis has impacted 52% 
of adults diabetics (CDC, 2008). 
2.4.1 Treatment 
Treatment is an essential part of diabetes management. Diabetes Type I is not 
curable, however the complications of Type II may be reversed with lifestyle changes 
(American Diabetes Association, 2013a). Both types involve taking medicines, regu-
lating diet, and exercising to control blood glucose levels (Topiwala, Zieve, VeriMed 
Healthcare Network, A.D.A.M. Health Solutions, & Ebix, 2012). Monitoring blood 
glucose levels are therefore critical to manage treatment. Hence, the American Diabe-






Glucometers are handheld devices designed to measure blood glucose level by 
chemically analyzing a small blood sample (Figure 5).  
 
Figure 5: Bayer® Contour® Next EZ Glucometer and Lancing Device. 
Typically, users are required to prick their finger using a Lancing Device. Af-
ter successfully extracting blood from the finger, users place a blood drop on a test 
strip which initiates a biochemical reaction with the glucose oxidase on each test 
strip. The meter translates the biochemical reaction into a numerical value, which is 
stored in the device and presented to the user on the screen. The process from placing 
the blood on the test strip to displaying the result takes about 5 seconds. Most of the 
time is spent preparing the device and extracting blood. Each test strip and lancet unit 
must be discarded after use. 
The ADA (American Diabetes Association, 2013a) recommends usage of glu-















control. Frequency of testing depends on different factors including the type of diabe-
tes, age, weight, medications, and exercise, among others.  Regular blood glucose 
testing allows diabetics to achieve and maintain glycemic goals (Goldstein et al., 
2004). Despite the benefits of using glucometers to monitor blood glucose levels, dia-
betes patients have lower rates of device use treatment adherence, ranging from 20% 
to 66% (Vincze, Barner, & Lopez, 2004), which  increases chances of health compli-





Chapter 3:   Methods 
This study was divided in two phases. First, an expert usability analysis (hier-
archical task analysis and usability heuristics), was performed on 13 glucometers to 
identify features and functions that contribute to device usability. The usability analy-
sis guided the identification of critical features for disabled users, to be further ex-
plored in a simulation study in the second phase. During the second phase, partici-
pants interacted with four meters and verbally expressed their satisfaction with each 
feature identified during the expert usability analysis. These two phases are detailed 
in subsequent sections. 
3.1 Phase 1: Expert Usability Testing 
Initially, 13 existing glucometers were selected for analysis (Table 1).  For 
each device, we developed detailed glucometer-specific hierarchical task analyses 
(HTA) (Kurniawan, 2003) and usability ratings based on Nielsen’s Ten Heuristics 
(Nielsen & Mack, 1994).  
3.1.1 Hierarchical Task Analysis  
To identify the task levels, a HTA was performed to determine the actions to 
fully operate a glucometer. HTA consists of determining high-level tasks and decom-
posed them into sub-tasks. Tasks and sub-tasks are subsequently organized as plans 
that illustrate how tasks can be performed. This method is useful to identify specific 




Table 1: Glucometer List 
Glucometer 
Brand Model 
OneTouch Verio IQ 
Bayer Contour USB 
Sanofi iBG Star 
OneTouch Ultra2 
Accu-Chek Nano 
Bayer Contour Next EZ 
Bayer Contour 
Accu-Chek Aviva Plus 
Abbott Precision Xtra 
OneTouch UltraMini 




Glucometer-specific HTAs were created after interacting with each device and 
thoroughly reading the instruction manual. An example HTA for the Bayer® 
Breeze®2 meter is shown in Appendix A. All HTAs contained six common high-
level tasks which include: Set Up Meter, Code Meter, Control Test, Prepare Lancing 
Device, Perform Test, and Review Past Results. Where appropriate, each high-level 
task was further divided into sub-tasks. 
3.1.2 Usability Heuristics 
Nielsen’s Ten Heuristics were used for the heuristic usability analysis of each 
glucometer HTA sub-task. A heuristic evaluation is a method that identifies usability 
issues by employing a small group of evaluators who examine a user interface with a 




user interfaces. The purpose of a heuristics evaluation is to elicit human error contrib-
utors or other sources for difficulty of device use. 
Table 2: Nielsen’s Ten Heuristics (Nielsen & Mack, 1994) 
 Heuristic Description 
1 Visibility of system status The system should always keep users informed about what is 
going on, through appropriate feedback within reasonable time. 
2 Match between system 
and the real world 
The system should speak the users' language, with words, 
phrases and concepts familiar to the user, rather than system-
oriented terms. Follow real-world conventions, making infor-
mation appear in a natural and logical order. 
3 User control and freedom Users often choose system functions by mistake and will need 
a clearly marked "emergency exit" to leave the unwanted state 
without having to go through an extended dialogue. Support 
undo and redo. 
4 Consistency and stand-
ards 
Users should not have to wonder whether different words, situ-
ations, or actions mean the same thing. Follow platform con-
ventions. 
5 Error prevention Even better than good error messages is a careful design which 
prevents a problem from occurring in the first place. Either 
eliminate error-prone conditions or check for them and present 
users with a confirmation option before they commit to the ac-
tion. 
6 Recognition rather than 
recall 
Minimize the user's memory load by making objects, actions, 
and options visible. The user should not have to remember in-
formation from one part of the dialogue to another. Instructions 
for use of the system should be visible or easily retrievable 
whenever appropriate. 
7 Flexibility and efficiency 
of use 
Accelerators -- unseen by the novice user -- may often speed 
up the interaction for the expert user such that the system can 
cater to both inexperienced and experienced users. Allow users 
to tailor frequent actions. 
8 Aesthetic and minimalist 
design 
Dialogues should not contain information which is irrelevant or 
rarely needed. Every extra unit of information in a dialogue 
competes with the relevant units of information and diminishes 
their relative visibility. 
9 Help users recognize, di-
agnose, and recover from 
errors 
Error messages should be expressed in plain language (no 
codes), precisely indicate the problem, and constructively sug-
gest a solution. 
10 Help and documentation Even though it is better if the system can be used without doc-
umentation, it may be necessary to provide help and documen-
tation. Any such information should be easy to search, focused 
on the user's task, list concrete steps to be carried out, and not 




Each glucometer was analyzed separately by three evaluators who assigned a 
score, from no usability problem (0) to severe usability issue (4). Single evaluators 
are able to find 35 percent of usability problems and the preferred number of evalua-
tors range between three and five (Nielsen, 1995). It’s important to note that although 
the HTA include non-device interaction tasks such as grabbing the meter and opening 
the button door (tasks 1.1.1-1.1.2 Appendix A: HTA for Bayer® Breeze®2); only the 
usability scores were applied to the tasks that involved device interaction. Additional-
ly, each evaluator listed all usability issues encountered during the analysis of devic-
es, with specific reference for tasks. Two of the evaluators had more than nine months 
of both human factors and usability experience and one of them had more than six 
months of experience. The summarized results of usability scores for each meter in-
cluded in Phase 1 can be found in Table 6. 
3.2 Phase 2: Disability Simulation User Testing 
Expert usability testing allowed for the identification of buttons and screens as 
the most influential usability features. In particular for disabled patients, these fea-
tures may have more influence on usability. Even though shape and size of meters 
were not found among the top influencers on usability, they were incorporated in the 
set of features to be evaluated during the user test to provide a more comprehensive 
evaluation. 
A group of modular components, Screen, Buttons, and Case, was defined 
based on the aforementioned features. Different characteristics of each modular com-
ponent were defined as well as a criterion to select devices to use during the test 




Chek® Nano, and Contour® USB (Figure 6)—that together spanned across all crite-
rion were selected (Table 3). Each meter represents a different modular component at 
a different scale, thus encompassing all features desired to be tested in Phase 2. 
Table 3: Physical Characteristics of Selected Glucometers 





Length > 4” 
Medium 
4” > Length > 3” 
Small 
Length < 3” 
Medium 
4” > Length > 3” 
Meter Shape Ellipse Oval Rectangle 
Rectangle 
(extended) 
Button Recessed Protruding Flush Protruding 
Button Size 
Medium 
7/16” > Length > 5/16” 
Large 
Length > 7/16” 
Medium 
7/16” > Length > 5/16” 
Small 
Length < 5/16” 
Screen Size 
Medium 
1.25in2 > Area > 1.75in2 
Large 
Area > 1.75in2 
Small 
Area < 1.25in2 
Medium 
1.25in2 > Area > 1.75in2 
Screen Shape Wide Upright Upright Wide Extended 
Screen Text 
Medium 
9/16” > Height > 5/16” 
Large 
Height > 9/16” 
Medium 









Based on the diabetes statistics, the two most common mobility (arthritis & 
diabetic neuropathy) and vision (glaucoma & diabetic retinopathy) impairments were 
selected as diseases to analyze during the user testing phase. A pilot test intended to 
evaluate the experimental protocol was conducted with nine healthy participants. As 
mentioned previously, the purchase of Phase 2 is to provide experimental protocol 
validation for future studies in the diabetic disabled population. Each healthy subject 
wore different instruments (glasses and gloves) intended to simulate each disability. 
3.2.1 Disease Simulators 
Diabetic retinopathy is the most common diabetic eye disease generated by 
damage to the blood vessels in the retina. Diabetes retinopathy involves blurred vi-
sion with floaters in the field of vision that eventually leads to blindness. A pair of 
glasses obtained from ShopLowVision (www.shoplowvision.com) was used to simu-
late floaters and spotty vision as shown in Figure 7. 
 




Glaucoma is the second most common cause of blindness in the United States 
caused by damage to the optic nerve due to increased pressure in the eye. Open-angle, 
the most common type of glaucoma, produces a loss of peripheral (side) vision and 
can also lead to blindness. Loss of side vision was simulated with Peripheral Field 
Loss glasses obtained from ShopLowVision. The Peripheral Field Loss glasses limit 
the visual field to 12 degrees when worn at an eyeglass position (Figure 8). 
 
Figure 8: Vision through Peripheral Field Loss glasses (glaucoma) 
Arthritis is a family of joint diseases including symptoms such as pain and 
joint stiffness. In the general case, a person affected by any form of arthritis has diffi-
culty moving the joints along with muscle weakness. Another prevalent mobility-
restriction disease among diabetic persons is diabetic neuropathy, which produces 
similar symptoms to arthritis including insensitivity to pain, muscle weakness, and 
loss of reflexes. Several arthritis and neuropathy simulation gloves are available for 
purchase; however, they are limited in their use for small handheld devices and ac-
commodation of multiple hand sizes. Nitrile gloves presented the best option to simu-




(arthritis) and touch desensitization (neuropathy) based on the number of layers worn. 
After testing several numbers of layers, five layers of gloves was selected since it 
provided sufficient joint restriction combined with finger sensitivity reduction (Figure 
9) compared with the commercial options available. Although some hand sweating 
from the nitrile gloves is expected, this was not a critical experimental factor based on 
the short amount of time the subjects spend wearing the gloves. 
 
Figure 9: Five layers of nitrile gloves 
3.2.2 Subject Population 
The standard number of accepted participants for usability studies is approxi-
mately five subjects.  Studies have shown that the proportion of discovered usability 
problems exponentially decrease for each participant after the fifth participant (Niel-
sen & Landauer, 1993). The study sought to recruit approximately ten participants to 
provide an experimental buffer, given the pilot stage of the project. A total of nine 
participants, eight males and one female, between the ages of 18 and 24 were recruit-
ed from two undergraduate Mechanical Engineering courses (ENME242 and EN-




quired to be over the age of 18 without existing hand mobility or vision limitations. 
However, participants with vision complications rectified with lenses were included 
in the study if prescribed corrective glasses were worn during the experiment. Each 
subject received extra credit of one homework (ENME242) or participation (EN-
ME371) grade in their respective class for participation. The University of Maryland 
Institutional Review Board (IRB) provided approval for this study by means of a let-
ter shown in Appendix E. 
3.2.3 Experimental Tasks 
The study consisted of three audio and video recorded tasks (Turn Meter On, 
Review Past Results, and Insert Test Strip) with all four glucometers while wearing 
one disease simulator at a time. Simple tasks were selected to minimize the confound-
ing effect of the subject’s perceived glucometer usability with their satisfaction of vi-
sion and mobility while using the meter. 
The first task, Turn Meter On, consisted of three major steps: 
• Visually locate the power button. 
• Manually press the power button. 
• Verify the meter is on by reading the date on meter out loud. 
Similarly, the second task, Review Past Results, was decomposed into the fol-
lowing major steps: 
• Visually locate the memory (or equivalent) button. 
• Manually press the memory button. 
• Read out loud the stored results and date it was entered. 




• Manually press the next-result button. 
• Read out loud a second stored results and date it was entered. 
Inserting the test strip into the meter was a more complex task that required 
hand-eye coordination with precision handling of the test strip. Completion steps are: 
• Visually locate the test strip. 
• Manually pick up the test strip. 
• Properly orient the test strip and visually confirm the orientation. 
• Insert the test strip into meter 
• Visually confirm the meter is ready for testing (test strip was success-
fully inserted). 
Prior to completion of the tasks, participants received a brief training with in-
structions on how to accomplish each task through the use of training materials 
shown in Appendix F. Subjects were allowed a short time (one minute) to familiarize 
themselves with the tasks and devices to minimize confounding learning curve re-
sults. In addition, instructions were provided while completing each task to eliminate 
instruction memorization during the training session.  
The study was designed following a within-subjects methodology. Partici-
pants experienced all independent variables (glucometers and disease simulators) in a 
randomized order to avoid the experimental impact of presentation order.  
As shown in Figure 10, subjects verbally answered one five-point Likert scale 
question after completing each task. Both Likert scales (Figure 11) were presented on 




on the question asked. A different set of questions was asked depending on the dis-
ease simulators worn by the participants while completing the task.  
Both visual simulators, glaucoma and diabetes retinopathy, had the same set 
of questions (denoted as set “a”, Table 4) focused on the difficulty of visually inter-
acting with the devices. In particular, difficulty for subjects to read text and their sat-
isfaction with the size of the text, screen, and buttons. 
 
Figure 10: User Testing Protocol. 
 





Table 4: Set of Questions “a” for glaucoma and diabetes retinopathy simulators (glasses) 
 Question 
After Task 1 1. How easy or difficult was it for you to see when performing Task 1 (power)? 
After Task 2 2. How easy or difficult was it for you to see when performing Task 2 (past re-sults)? 
After Task 3 
3. How easy or difficult was it for you to see when performing Task 3 (test 
strip)? 
4. How easy or difficult was it for you to read the text? 
5. How would you rate your overall satisfaction with the size of the screen text? 
6. How would you rate your overall satisfaction with the shape and size of the 
screen? 
7. How would you rate your overall satisfaction with the shape and size of the 
buttons 
 
Mobility simulator (gloves) had a set of questions “b” centered on the difficul-
ty of manually interacting with glucometers (Table 5). Specifically, the difficulties for 
participants to feel the buttons, press the buttons, grasp the meter, and hold the meter 
for an extended period of time. 
Subjects then verbally answered open-ended questions meant to summarize 
their overall experience after completing all tasks with each simulator. Four open-
ended questions were asked, requiring verbal response:  
• After interacting with the meters, which one do you prefer? Why? 
• What was the most difficult part of [visually/manually] interacting 




• Is there any screen, button or shape feature of the meters that was re-
stricting? 
• Could you think of any new meter feature that would help while per-
forming the tasks? 
Table 5: Set of Questions “b” for arthritis and neuropathy simulators (gloves) 
 Question 
After Task 1 1. How easy or difficult was it for you to use your hands to perform Task 1 (power)? 
After Task 2 2. How easy or difficult was it for you to use your hands to perform Task 2 (past results)? 
After Task 3 
3. How easy or difficult was it for you to use your hands to perform Task 3 (test 
strip)? 
4. How easy or difficult was it for you to feel the buttons? 
5. How easy or difficult was it for you to press the buttons?  
6. How easy or difficult was it for you to grasp the meter? 
7. How would you rate your overall satisfaction with the shape and size of the 
buttons 
8. How would you rate your overall satisfaction with the weight of the meter? 
9. How easy or difficult was it for you to hold the meter for a period of time? 
 
3.2.4 Statistical Analysis: Friedman Test 
For each question, we sought evidence in support of a statistical difference be-
tween the responses of all four meters. For this we performed several Friedman Rank 




is adequate for non-numeric related ordinal data. All the following required assump-
tions are met: 
• One group that is measured on three or more different occasions. 
• Group is a random sample from the population. 
• The dependent variable should be measured at the ordinal or continu-
ous level. 
• Samples do not need to be normally distributed. 
For every Friedman Test, the null hypothesis and alternative hypothesis were 
set as the following H0: No difference in preference of meters and  H1: Some meters 
tend to be preferred over the others. Each question consisted of 9=b mutually inde-
pendent blocks (participants) with 4=k  treatments (glucometers). Scores assigned 
by each participant were ranked and a value of 1 was given to the smallest observed 
value, 2 to the second smallest, and so on. Average ranks were used in case of ties.  
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where R(Xij) is the rank assigned to the X score by the i-th participants for the j-th me-
ter. The sum of the squares of the ranks A1 and correction factor C1 were computed 
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However, a more accurate approximation for T1 is provided by Equation (5) below. 








=  (5) 
The null hypothesis is rejected at an 05.0=α significance level if T2 exceeds 
the α−1  quantile of the F distribution for 11 −= kk  and ( )( )112 −−= kbk . 
If the Friedman test rejects the null hypothesis, multiple pair comparisons can 
be made to determine which meter is statistically preferred by the user. A pair of me-
ters can be compared with Equation (6) and one of them is considered preferred by 
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Chapter 4:   Results 
4.1 Phase 1: Expert Usability Testing 
Thirteen glucometers were analyzed during Phase 1 (Expert Usability Analy-
sis). For each device a HTA was created and a usability score was assigned to inter-
face tasks by three different evaluators. HTA for Bayer® Breeze®2, Accu-Chek® 
Aviva, Accu-Chek® Nano, and Bayer® Contour® USB can be found on Appendix 
A, Appendix B, Appendix C, and Appendix D, respectively. The sum of usability 
scores from the three evaluators is also presented. The maximum value for the com-
bined usability score is 120. Usability scores were assigned from 0 (no usability is-
sues), to 4, (severe usability issue). Therefore, for values in Appendices, a high usa-
bility score denotes a glucometer that did not demonstrate high usability and vice ver-
sa. 
Each glucometer had three usability scores, one from each evaluator, which 
were aggregated through summation and then normalized by the maximum possible 
usability score. As a result, high usability scores indicate glucometers with higher us-
ability in Table 6. The glucometers with the highest usability, in ascending order, 
were iBG® Star, Bayer® Contour® USB, and OneTouch® Verio® IQ. On the other 
hand, the glucometers with the lowest usability, in descending order, were Accu-








OneTouch Verio IQ 0.936 
Bayer Contour USB 0.850 
Sanofi iBG Star 0.781 
OneTouch Ultra2 0.640 
Accu-Chek Nano 0.622 
Bayer Contour Next EZ 0.577 
Bayer Contour 0.569 
Accu-Chek Aviva Plus 0.551 
Abbott Precision Xtra 0.532 
OneTouch UltraMini 0.519 
Accu-Chek Compact Plus 0.406 
FreeStyle Lite 0.381 
Bayer Breeze2 0.380 
 
Moreover, evaluators listed all the features contributing to usability encoun-
tered during the usability test (Table 7). Features were divided into positive and nega-
tive contributors. As expected, glucometers with higher usability possessed more pos-
itive features than negative ones. 
The screen or display was the most impactful feature. Non-segment screens 
positively contributed to usability (top 4 devices) and segment screens negatively 
contributed (bottom 9 devices). Refer to Figure 12 for an example of segment and 




formation must be adapted to the display configuration, which complicates the setup 
process and marking results. 
 
Figure 12: Segment and non-segment display 
Buttons themselves were not frequently listed as an influential feature; how-
ever, many other functions depend on it: setup process, tagging, and viewing results. 
Therefore buttons and screens were analyzed during Phase 2, Disability Simulation 
User Testing. 
Table 7: Identified usability contributing features. 
Glucometer Features 
Brand Model Pros Cons 
OneTouch Verio IQ 
 Non-segment display -- Test strip port with uncon-
ventional shape and loca-
tion.  
-- Rechargeable battery 
-- Notes for results 
 Uses language 
 Light for test strip port 
 Clear test strip port win-
dow 
-- High/low glucose pattern 
recognition 







 Non-segment display -- Lancing device difficult to 
use. 
 
-- Rechargeable battery 
-- Notes for results 
 Uses language 
 ATM style buttons  Small screen 
 Light for test strip port 
-- Connectivity with com-
puter via USB                                                                                
 Short test time 
Sanofi iBG Star 
 
 
No setup necessary -- Poor usability without mo-
bile phone 
 Small size 
-- Connectivity with phone 
via module connector 
-- High cost 
 Attractive interface 
-- Rechargeable battery -- Mobile capabilities unex-
ploited 
 Clear test strip port win-
dow 
OneTouch Ultra2 
 Non-segment display -- Coding Required 
 Uses Language -- Complicated Result Tags 
Process 
 Screen Light 
-- Notes for Results                                                                             Past Results Layout 
-- Short test time 
Accu-Chek Nano 









 Large Intuitive Icons   
 
Complicated set-up 
 Segment display 
-- Lancing device difficult to 
use 
 Unintuitive buttons 
Bayer Contour 
 Large Intuitive Icons   
 
Complicated set-up 
 Segment display 
-- Lancing device difficult to 
use 




Accu-Chek Aviva Plus 
-- Lancing Device -- - Coding Required 
 Dedicated Power button  Segment display 




-- Monitors Ketones 
 
-- Coding required 
-- Test strip foil packaging 
 Light-up display  No mark result possibility 
 Segment display 
-- Lancing device difficult to 
use 
OneTouch UltraMini 
 Large display -- Coding required 
 Small device size                                                                                         -- No test averages
 Segment display 
-- Short Test time  
 
Confusing setup 




-- Test strip drum 
 
-- Test strip mechanism com-
plicated 
 Bulky meter 
-- Lancing device simple op-
eration 
-- Too much blood required 
 Unintuitive buttons 
 Segment display 
FreeStyle Lite 
 Screen light  Unintuitive buttons 
 Test strip port light  Segment display 
 Graphics on test strip al-
low to easily orient strip                                                            
-- Lancing device difficult to 
use
-- Short test time 
Bayer Breeze2 
 Test strip drum (10 strips) 
removes the need to insert 
strip for each test 
-- Lancing Device difficult to 
use 
-- Test strip mechanism 
 Segment Display 




Test strip drum has com-
plicated insertion and re-
moval 




4.2 Phase 2: Disability Simulation User Testing 
Participant answers to each question were analyzed by means of a Friedman 
Test as described in Section 3.2.4. Questions were organized by difficulty to complete 
task as well as by major modular feature (screen, buttons, and casing). Comprehen-
sive analysis of the results is presented in Appendix G and summary of statistical 
analyses are shown per modular feature in this section. 
The first three questions were grouped by general difficulty to complete the 
tasks with each meter (Table 8). No statistical difference was found among glucome-
ters for Task 1 with any of the disease simulators (Retinopathy P-value = 0.681; 
Glaucoma P-value = 0.384; and Arthritis + Neuropathy P-value = 0.187). This sug-
gests that the importance of the power button is minimal. In real conditions the inter-
action with the power button is also minimal and some glucometers do not require 
pressing the power button to turn on the glucometer. Conversely, a significant differ-
ence was found among glucometers for Task 2 with all disease simulators (Retinopa-
thy P-value = 0.042; Glaucoma P-value < 0.001; and Arthritis + Neuropathy P-value 
< 0.001). For both vision disease simulators, Retinopathy and Glaucoma, the glu-
cometers Accu-Chek® Aviva and Bayer® Breeze®2 performed better than Accu-
Chek® Nano and Bayer® Contour® USB due the more intuitive and larger control 
buttons. Task 3 presented similar results as Task 1 with no statistical difference 
among glucometers for any of the disease simulators (Retinopathy P-value = 0.262; 





Table 8: Statistics Summary for first three questions grouped by meter (α=0.05) 
 
Q1: Turn On Meter Q2: Review Past Results Q3: Insert Test Strip 
Retinopathy 
Accept H0 Reject H0 Accept H0 
T2 = 0.508; 
P-value = 0.681 
T2 = 3.197; 
P-value = 0.042 
T2 = 1.418; 
P-value = 0.262 
No statistical difference • Breeze2 is preferred 
over USB 
• Aviva is preferred over 
USB 
No statistical difference 
Glaucoma 
Accept H0 Reject H0 Accept H0 
T2 = 1.061; 
P-value = 0.384 
T2 = 9.617; 
P-value < 0.001 
T2 = 0.188; 
P-value = 0.904 
No statistical difference • Breeze2 is preferred 
over Nano 
• Breeze2 is preferred 
over USB 
• Aviva is preferred over 
Nano 
• Aviva is preferred over 
USB 
No statistical difference 
Arthritis + 
Neuropathy 
Accept H0 Reject H0 Accept H0 
T2 = 1.734; 
P-value = 0.187 
T2 = 13.158; 
P-value < 0.001 
T2 = 0.875; 
P-value = 0.468 
No statistical difference • Aviva is preferred over 
Breeze2 
• Aviva is preferred over 
Nano 
• Aviva is preferred over 
USB 















Screen related questions are shown in Table 9. No difference was found 
among glucometers for the two visual simulators for ease of reading text (Retinopathy 
P-value = 0.228; and Glaucoma P-value = 0.144) and text satisfaction (Retinopathy 
P-value = 0.441; and Glaucoma P-value = 0.107). This results indicates that the dif-
ference in text height was not sufficient to produce a variation in participant response. 
Subjects preferred the Accu-Chek® Aviva screen while wearing the retinopathy 




ly by participants while answering the open-ended questions. For glaucoma, partici-
pants did not have a preference among glucometers (Glaucoma P-value = 0.11). 
Table 9: Statistics Summary for screen related questions (α=0.05) 
 
Q4a: Ease of Text     
Reading Q5a: Text Satisfaction 
Q6a: Screen               
Satisfaction 
Retinopathy 
Accept H0 Accept H0 Reject H0 
T2 = 1.545; 
P-value = 0.228 
T2 = 0.931; 
P-value = 0.441 
T2 = 3.277; 
P-value = 0.038 
No statistical difference No statistical difference • Aviva is preferred over 
Nano 
• Aviva is preferred over  
USB 
Glaucoma 
Accept H0 Accept H0 Accept H0 
T2 = 1.976; 
P-value = 0.144 
T2 = 2.261; 
P-value = 0.107 
T2 = 2.237; 
P-value = 0.11 
No statistical difference No statistical difference No statistical difference 
 
Subjects favored large protruding buttons as can be seen in Table 10. Button 
satisfaction exhibited a difference among glucometers for all disease simulators (Ar-
thritis + Neuropathy P-value = 0.045; Glaucoma P-value = 0.008; and Retinopathy P-
value < 0.001). Accu-Chek® Aviva, with large protruding buttons, had the greatest 
satisfaction among all glucometers for all three simulators. On the opposite side is 
Bayer® Contour® USB that had the lowest statistical rank (preference) compared to 
the rest of devices. Color contrast between the case and buttons and size of buttons 
were important for satisfaction rating. The ease of button touching (Arthritis + Neu-
ropathy P-value = 0.325) and pressing (Arthritis + Neuropathy P-value = 0.258) 
showed no significant difference between glucometers suggesting that both tasks 




Table 10: Statistics Summary for button related questions (α=0.05) 
 
Q4b: Ease of Button 
Feeling 
Q5b: Ease of Buttons 
Pressing Q7: Button Satisfaction 
Arthritis + 
Neuropathy 
Accept H0 Accept H0 Reject H0 
T2 = 1.217; 
P-value = 0.325 
T2 = 1.434; 
P-value = 0.258 
T2 = 3.12; 
P-value = 0.045 
No statistical difference No statistical difference • Aviva is preferred over 
Breeze2 
• Aviva is preferred over  
Nano 
• Aviva is preferred over  
USB 
Glaucoma --- --- 
Reject H0 
T2 = 4.986; 
P-value = 0.008 
• Aviva is preferred over  
Breeze2 
• Breeze2 is preferred 
over  USB 
• Aviva is preferred over  
USB 
• Nano is preferred over  
USB 
Retinopathy --- --- 
Reject H0 
T2 = 8.544; 
P-value < 0.001 
• Aviva is preferred over  
Breeze2 
• Aviva is preferred over  
Nano 
• Aviva is preferred over  
USB 
 
The weight of meters presented a similar trend across all meters as shown in 
Table 11. Meter weight was not significantly different (Arthritis + Neuropathy P-
value = 0.441) among all devices,, which demonstrates that weight is not an im-
portant variable for the users. Bayer® Breeze®2 and Accu-Chek® Aviva were the 
easiest to grab compared to Accu-Chek® Nano mainly due to the size and shape of 






restriction. The size of Accu-Chek® Nano, with the lowest statistical rank (prefer-
ence) among all meters, did not easily enable users to grab the meter. No difference 
was found among glucometers for holding the device for a period of time (Arthritis + 
Neuropathy P-value = 0.057).  
Table 11: Statistics Summary for meter case related questions (α=0.05) 
 
Q6b: Ease of Meter  
Grabbing  
Q8b: Meter Weight   
Satisfaction 




Reject H0 Accept H0 Accept H0 
T2 = 3.388; 
P-value = 0.034 
T2 = 0.93; 
P-value = 0.441 
T2 = 2.875; 
P-value = 0.057 
• Breeze2 is preferred 
over  Nano 
• Aviva is preferred over  
Nano 
No statistical difference No statistical difference 
 
Open-ended questions gave participants freedom to express any frustration or 
satisfaction with each meter. Reoccurring statements were used to diagnose issues, 
provide possible solutions, and inform study design options for future data collection 
in the diabetes patient population. The recurrent statements on difficulties included: 
• Low color contrast between text and the screen background. 
• Low color contrast between case and buttons to easily locate buttons. 
• Low contrast between test strip port and case (or depressed strip port) 
• Protruding buttons too close together that do not allow distinguishing 
buttons. 







Color and contrast were crucial for participants’ interaction with the meters, 
especially while wearing glaucoma and diabetes retinopathy simulators. Color al-
lowed subjects to rapidly guide themselves to locate elements as well as read the text. 








Chapter 5:   Discussion  
Glucometer usability is essential due to high percentage of diabetes patients 
over the age of 65 who suffer physical impairments that may negatively impact their 
device use. Failure to match patients to a suitable device can lead to improper use, 
non-adherence to instructions, and poor outcomes. Diabetes patients exposed them-
selves to serious health complications if they do not adherence to recommended glu-
cometer use due to poor disease management. Heath complications increase both 
mortality and morbidity rates (Ho, Rumsfeld, Masoudi, & et al, 2006), which is a 
common consequence of non-adherence among all chronic diseases. 
Despite the fact that chronic disease patients develop similar debilitating dis-
ease complications (vision, mobility, hearing), each patient will present a different 
health condition, which will shape device interaction needs. A potential solution in-
volves customizing devices features through modularity to meet individual needs. 
Modular architecture applied to handheld medical device design can provide distinc-
tive modules for each feature (Figure 13). 
5.1 Main Findings 
Individuals with disabilities have different device preferences according based 
on their limitations. Persons with limited visibility focus on screen characteristics and 
prefer upright large screens. Buttons, which is an interest for individuals with mobili-
ty restriction, should have a large size and be located in the front of the device. In ad-






button location with less finger sensitivity. Color contrast is also an important feature 
because it allows important components such as buttons, text, and the test strip port to 
be easily perceived. 
5.2 Modular Design Concepts 
The concept of segmenting service functions into modules has been applied in 
the health services domain because of the inherent differences in user needs and ca-
pabilities (Blok, Luijkx, Meijboom, & Schols, 2010; Chorpita, Daleiden, & Weisz, 
2005). Here it is proposed to design functional device variety to serve users with a 
range of capabilities. The screen module can be swapped to meet the users’ visual re-
quirements. Similarly, the button module can provide different protruding and space 
configurations. Handling and grabbing is achieved by means of shape modules that 
alter device shape to meet users hand size and mobility limitations. The rightmost 
glucometer concept in Figure 13 illustrates the adaptability of modular architecture, 
which can meet needs of disabled user and those without disabilities. 
 






The design process can integrate empirically defined patient characteristics 
with the iterative design of modular hardware and software components to insure that 
the device takes into account the individual patient needs to technologically support 
patient limitations, functional impairment, and relevant self-management activities. 
Operation of the new device can reduce human inputs and improve device-user com-
munication, thus reducing user workload during operation, particularly for user with 
disabilities. For instance, buttons could be replaced by a voice commands feature and 
the screen interaction could be minimized with voice over capabilities. 
Another design concept example is a bracelet glucometer (Figure 14) depicts 
which has the ability to reduce required human inputs by implementing non-invasive 
near infrared light spectroscopy. The user will not need to constantly prick their fin-
ger and could control the bracelet glucometer with voice commands. The device will 
immediately measure the glucose level and display it on the screen as well as read it 
out loud.  
5.3 Regulatory Implications 
In addition to the role of the designer, regulatory agencies, such as the FDA, 
should enforce the design and approval of new medical devices that meet the needs of 
all types of end-users, particularly when disabled users are the majority of the user 
population. Moreover, FDA should consider implementing design guidelines for 







Figure 14: Bracelet Glucometer Design Concept 
Design guidelines can eliminate the necessity for manufactures to conduct 
human factors analyses. Typically, manufactures perform analytical methods and 
formative evaluations to ensure component dimensions meet all types of end-user re-
quirements. Although design guidelines remove the burden from manufacturers, ad-
herence to standardized guidelines can be translated into both costs and time reduc-
tion. Regulatory resources can also be reduced by use of design guidelines than en-






Chapter 6:   Conclusions 
The current study identified device screens and buttons as the principal fea-
tures impacting usability. A disability simulation study of these features with other 
physical characteristics of glucometers suggests that handheld medical devices for pa-
tients with disabilities require large protruding buttons, mid-size oval shaped casings, 
and large screens. Color is equally important for device design since contrast facili-
tates the location of important device elements such as text, buttons, and strip port. 
Limitations of the current study—sample size and disease simulations—restrain the 
generalization of findings, however, these will be addressed in future studies in the 
actual disease population. 
Future work will aim to expand these tests in a stratified population usability 
study focused on diabetic patients with a mobility or vision impairment. Hearing im-
pairment will also be included in next phases of this study. Findings could potentially 
support the FDA in developing handheld medical device design guidelines for healthy 
and disabled end-users. These guidelines can recommend physical dimensions for dif-
ferent device features such as meter shape, meter dimension, screen size, screen text 
size, buttons installation type, buttons size, and use of color. Manufacturers can also 
potentially benefit from the results by considering them during the design process in 
addition to usability testing. Ultimately, development of a new glucometer that fits 








Appendix A: HTA for Bayer® Breeze®2 
U.S. denotes usability score. 
Hierarchical Task Analysis U.S. 
Task Description Total 
1.0 Set up Meter   
 1.1 Set Time  
  1.1.1 Grab and Hold the meter  
  1.1.2 Open the button door  
  1.1.3 Press and release the Setup Button  
72 
  1.1.4 Press the Up and/or Down buttons to set desired hour number 
  1.1.5 Press and release the OK Button to save and confirm hour number 
  1.1.6 Press the Up and/or Down buttons to set desired minutes number 
  1.1.7 Press and release the OK Button to save and confirm minutes number 
  1.1.8 Press the Up and/or Down buttons to AM or PM 
  1.1.9 Press and release the OK Button to save and confirm the AM or PM 
 1.2 Set Date  
  1.2.1 Press the Up and/or Down buttons to desired date number 
72 
  1.2.2 Press and release the OK Button to save and confirm date number 
  1.2.3 Press the Up and/or Down buttons to desired month number 
  1.2.4 Press and release the OK Button to save and confirm month number 
  1.2.5 Press the Up and/or Down buttons to desired year number 
  1.2.6 Press and release the OK Button to save and confirm year number 
 1.3 Set the buzzer level  
  1.3.1 Press the Up and/or Down buttons to desired volume level 62 
  1.3.2 Press and release the OK Button to save and confirm the volume level 
 1.4 Set formats  
  1.4.1 Press the Up and/or Down buttons to desired time format  
72   
1.4.2 Press and release the OK Button to save and confirm time format 
  1.4.3 Press the Up and/or Down buttons to desired date format  
  1.4.4 Press and release the OK Button to save and confirm date format 
2.0 Inserting the strip disc  
 2.1 Hold the meter  
 2.2 Turn the meter (display facing down)  
 2.3 Press the open latch   






 2.5 Grab the test disc package  
 2.6 Peel the plastic cover of the disc package  
 2.7 Grab the test disc  
 2.8 Extract the test disc from package  
 2.9 Check expiration date in test disc  
 2.10 Properly orient the test disc  
 2.11 Align the test disc notches with the tabs in the meter  
 2.12 Insert the test disc in meter  
 2.13 Keep the meter flat  
 2.14 Grab the meter's back cover  
 2.15 Close the meter  
3.0 Control Test  
 3.1 Gather all the necessary materials  
 3.2 Grab the meter  
 3.3 Hold the meter firmly with one hand  
 3.4 Grasp the meter handle with the other hand  
 3.5 Pull the meter handle out until it stops  
 3.6 Push the meter handle in until it stops  
 3.7 Grab the control solution bottle  
 3.8 Grab the bottle's cap  
 3.9 Twist the cap to remove it  
 3.10 Squeeze the control solution bottle  
 3.11 Place a drop of control solution onto a non-absorbent surface  
 3.12 Grab the bottle's cap  
 3.13 Properly orient the bottle's cap  
 3.14 Twist the cap until it stops  
 3.15 Grab the meter   
 3.16 Properly orient the meter  
 3.17 Position the meter next to the solution drop  
 3.18 Touch the solution drop to the front edge of the test strip  
 3.19 Wait while the meter measures the glucose level  
 3.20 The result is displayed   
 3.21 Open the button door  
 3.22 Press and release the Up button  
 3.23 Press the OK button accept the result as marked  
 3.24 Grab the Control Range Card  
 3.25 Check if result is in range for the solution control level  
 3.26 Grab the meter  
 3.27 Hold the meter with the test strip pointing down  
 3.28 Make sure nothing is blocking the strip  






 3.30 Press the Release Button  
 3.31 Pull out the test strip from meter  
 3.32 Press the Power Button to turn off the meter  
 3.33 Discard the test strip  
 3.34 Store meter  
4.0 Prepare Lancing Device  
 4.1 Gather the materials  
 4.2 Grab the Lancing Device  
 4.3 Pull out the lancing device cap  
 4.4 Grab a lancet  
 4.5 Twist the lancet protective cap to loosen it  
 4.6 Properly orient the lancet  
 4.7 Insert the lancet into lancing device's lancet holder  
 4.8 Push the lancet until it stops  
 4.9 Hold the lancet cover  
 4.10 Twist the lancet cover  
 4.11 Remove the lancet cover  
 4.12 Grab the lancing device cap  
 4.13 Properly orient the lancing device cap  
 4.14 Replace the lancing device cap  
 4.15 Rotate the depth dial to select the desired penetration depth  
 4.16 Grab the cocking handle  
 4.17 Pull out the cocking handle  
5.0 Glucose Test  
 5.1 Gather the materials  
 5.2 Wash hands  
 5.3 Grab the meter  
 5.4 Press and release the Power button 92 
 5.5 Verify that test strips are still available 
 5.6 Hold the meter firmly with one hand  
 5.7 Grasp the meter handle with the other hand  
 5.8 Pull the meter handle out until it stops  
 5.9 Push the meter handle in until it stops 89 
 5.10 Verify that a test strip came out  
 5.11 Verify that the meter is ready for the test  
 5.12 Grab the Lancing Device  
 5.13 Position and hold the lancing device firmly against the side of the fingertip  
 5.14 Press the release button on the lancing device with thumb   
 5.15 Gently squeeze the finger to promote blood flow  
 5.16 Grab the Meter  






 5.18 Position the meter next to the blood drop  
 5.19 Touch the blood drop to the front edge of the test strip 
75  5.20 Wait while the meter measures the glucose level 
 5.21 The result is displayed  
 5.22 Hold the meter with the test strip pointing down  
 5.23 Make sure nothing is blocking the strip  
 5.24 Make sure nothing is blocking the meter handle  
 5.25 Press the Release Button  
 5.26 Pull out the test strip from meter  
 5.27 Press the Power Button to turn off the meter  
 5.28 Grab the lancing device  
 5.29 Pull out the lancing device cap  
 5.30 Grab the previously removed protective lancet cover  
 5.31 Place the protective lancet cover to used lancet on a flat surface  
 5.32 Push the needle completely into the middle of the cap  
 5.33 Press and hold the release button  
 5.34 Grab the cocking handle  
 5.35 Pull the cocking handle to release the lancet  
 5.36 Grab the lancing device cap  
 5.37 Properly orient the lancing device cap  
 5.38 Replace the lancing device cap  
 5.39 Dispose lancet  
 5.40 Discard the test strip  
 5.41 Store meter and lancing device  
6.0 Review Results  
 6.1 Review Individual results  
  6.1.1 Grab the meter  
  6.1.2 Open the button door  
  6.1.3 Press and release the Memory Button  
49   6.1.4 Press the Up and/or Down buttons to view the stored results 
  6.1.5 Press and release the Power Button 
 6.2  Review Average results  
  6.2.1 Grab the meter  
  6.2.2 Open the button door  
  6.2.3 Press and release the Memory Button  
58   
6.2.4 Press and release the Memory Button  
  6.2.5 Press the Up and/or Down buttons to view the different averages 
  6.2.6 Press and release the Power Button 
 6.3 Clear Stored results  
  6.3.1 Grab the meter  






  6.3.3 Press and release the Memory Button  
103 
  6.3.4 Press and hold the Memory Button  
  6.3.5 Press and hold the Setup Button  
  6.3.6 Release buttons when 3 dashes appear 







Appendix B: HTA for Accu-Chek® Aviva 
U.S. denotes usability score. 
Hierarchical Task Analysis U.S. 
Task Description Total 
1.0 Set up Meter  
47 
 1.1 Set Time 
  1.1.1 Press Right and/or Left buttons to the desired hour number 
  1.1.2 Press Power Button to confirm the hour number 
  1.1.3 Press Right and/or Left buttons to the desired minute number 
  1.1.4 Press Power Button to confirm the minute number 
  1.1.5 Press Right and/or Left buttons for AM or PM 
  1.1.6 Press Power Button to confirm AM or PM 
 1.2 Set Date 
  1.2.1 Press Right and/or Left buttons to the month number 
  1.2.2 Press Power Button to confirm the month number 
  1.2.3 Press Right and/or Left buttons to the desired day number 
  1.2.4 Press Power Button to confirm the day number 
  1.2.5 Press Right and/or Left buttons for the desired year number 
  1.2.6 Press Power Button to confirm the year number 
2.0 Code the meter  
 2.1 Code the meter  
  2.1.1 Open the test strip box  
  2.1.2 Take out the container and code key  
  2.1.3 Make sure the number in code key matches the number in container  
  2.1.4 Insert the code key in the meter  
 2.2 Make sure the display is working properly  
  2.2.1 Turn off the meter or make sure the meter is off  
  2.2.2 Press and Hold (keep holding until end of the display test) the Power Button 
80   2.2.3 Wait for the meter to display the "checking pattern" 
  2.2.4 Compare the display on the meter with the picture in manual 
3.0 Control Test  
 3.1 Take out a test strip from the container  
 3.2 Insert test strip into the meter  
 3.3 Wait for the meter to display the code number  
 3.4 
Make sure the code number displayed in the meter matches the code number 
labeled on the container  






 3.6 Place meter on a flat surface  
 3.7 Select the solution level (meter comes with solution level 1) for the test  
 3.8 Remove the control bottle cap  
 3.9 Wipe the tip of the bottle with a tissue  
 3.10 Squeeze the bottle until a drop forms at the tip  
 3.11 Touch the drop to the front edge of the test strip  
 3.12 Wait for the meter to process information  
 3.13 Wipe the tip of the bottle with a tissue  
 3.14 Cap the solution bottle  
 3.15 
Press Right button (twice if necessary to set level 2) to specify the solution 
level used  
 3.16 Press the Power button to set the control level in the meter  
 3.17 Remove the test strip and discard  
4.0 Prepare Lancing Device  
 4.1 Get a lancet drum  
 4.2 Remove the lancing device's cap by pulling it out  
 4.3 Remove the used lancet drum from the lancing device  
 4.4 Insert the new lancet drum into the lancing device  
 4.5 Replace the lancing device's cap  
 4.6 Adjust the lancet depth  
5.0 Glucose Test  
 5.1 Gather materials  
 5.2 Check to see if the lancet drum in the lancing device needs to be changed  
 5.3 Change lancet  
  5.3.1 Get a lancet drum  
  5.3.2 Remove the lancing device's cap by pulling it out  
  5.3.3 Remove the used lancet drum from the lancing device  
  5.3.4 Insert the new lancet drum into the lancing device  
  5.3.5 Replace the lancing device's cap  
  5.3.6 Adjust the lancet depth  
 5.4 Wash hands  
 5.5 Get test strip  
 5.6 Insert the test strip into the meter 
65  5.7 
Make sure the code number displayed on the meter matches the code number 
on the test strip container label 
 5.8 Wait for the meter to be ready for the test 
 5.9 Prick finger  
  5.9.1 Hold the lancing device firmly against the side of the fingertip  
  5.9.2 Press the plunger on the end of the lancing device all the way down  
  5.9.3 Gently squeeze the finger to promote blood flow  
 5.10 Touch the blood drop to the front edge of the yellow window of the test strip 49 






 5.12 Observe the glucose reading 42 
 5.13 Mark the result  
 5.14 Remove the test strip and discard  
 5.15 Slide the lancing device lever to advance the lancet for the next use.  
 5.16 Wash hands  
6.0 Review Results  
 6.1 Grab the meter  
 6.2 Press and release the Power button 40 






Appendix C: HTA for Accu-Chek® Nano 
U.S. denotes usability score. 
Hierarchical Task Analysis U.S. 
Task Description Total 
1.0 Set up Meter   
 1.1 Set hour 
52 
  1.1.1 Press Right and/or Left buttons to the desired hour number 
  1.1.2 Press Power Button to confirm the hour number 
  1.1.3 Press Right and/or Left buttons to the desired minute number 
  1.1.4 Press Power Button to confirm the minute number 
  1.1.5 Press Right and/or Left buttons for AM or PM 
  1.1.6 Press Power Button to confirm AM or PM 
 1.2 Set date 
52 
  1.2.1 Press Right and/or Left buttons to the month number 
  1.2.2 Press Power Button to confirm the month number 
  1.2.3 Press Right and/or Left buttons to the desired day number 
  1.2.4 Press Power Button to confirm the day number 
  1.2.5 Press Right and/or Left buttons for the desired year number 
  1.2.6 Press Power Button to confirm the year number 
 1.3 Set up Reminders 
52 
  1.3.1 Press Right and/or left buttons to  desired beeper setting 
  1.3.2 Press Power Button to confirm the beeper setting  
  1.3.3 Press Right and/or Left buttons to desired reminder time 
  1.3.4 Press Power button to confirm desired reminder time 
  1.3.5 Press the Right and/or left buttons to desired test reminder setting 
  1.3.6 Press the Power button to confirm the test reminder setting  
  1.3.7 Repeat steps 1.3.5-1.3.6 for the second reminder test setting.  
2.0 Control Test  
 2.1  Gather materials  
 2.2 Make sure the display is working properly  
  2.2.1 Turn off the meter or make sure the meter is off  
  2.2.2 Press and Hold (keep holding until end of the display test) the Power Button  
  2.2.3 Wait for the meter to display the "checking pattern"  
  2.2.4 Compare the display on the meter with the picture in manual  
 2.3 Perform a control solution test  
  2.3.1 Take out a test strip from the container  






  2.3.4 Wait for the meter to be ready for the test  
  2.3.5 Place meter on a flat surface  
  2.3.6 Select the solution level (meter comes with solution level 1) for the test  
  2.3.7 Remove the control bottle cap  
  2.3.8 Wipe the tip of the bottle with a tissue  
  2.3.9 Squeeze the bottle until a drop forms at the tip  
  2.3.10 Touch the drop to the front edge of the test strip  
  2.3.11 Wait for the meter to process information and display result  
  2.3.12 Check to see if the result displayed matches the control range listed on the control solution bottle  
  2.3.13 Wipe the tip of the bottle with a tissue  
  2.3.14 Cap the solution bottle  
  2.3.15 Remove the test strip and discard  
3.0 Set up Lancing Device  
 3.1 Get a lancet drum  
 3.2 Remove the lancing device's cap by pulling it out  
 3.3 Remove the used lancet drum from the lancing device  
 3.4 Insert the new lancet drum into the lancing device  
 3.5 Replace the lancing device's cap  
 3.6 Adjust the lancet depth  
4.0 Perform Test  
 4.1 Gather materials  
 4.2 Check to see if the lancet drum in the lancing device needs to be changed  
 4.3 Change lancet  
  4.3.1 Get a lancet drum  
  4.3.2 Remove the lancing device's cap by pulling it out  
  4.3.3 Remove the used lancet drum from the lancing device  
  4.3.4 Insert the new lancet drum into the lancing device  
  4.3.5 Replace the lancing device's cap  
  4.3.6 Adjust the lancet depth  
 4.4 Wash hands  
 4.5 Get test strip  
 4.6 Check the Use By date on the test strip container to make sure it is still valid   
 4.7 Insert the test strip into the meter 
42 
 4.8 Wait for the meter to be ready for the test 
 4.9 Prick finger  
  4.9.1 Hold the lancing device firmly against the side of the fingertip  
  4.9.2 Press the plunger on the end of the lancing device all the way down  
  4.9.3 Gently squeeze the finger to promote blood flow  
 4.10 Touch the blood drop to the front edge of the yellow window of the test strip  






 4.12 Observe the test result and select the desired marker 
  4.12.1 Press the right arrow button to choose the appropriate marker 
  4.12.2 Remove the test strip  
 4.13 Remove the test strip and discard  
 4.14 Slide the lancing device lever to advance the lancet for the next use.  
 4.15 Wash hands  
5.0 View Results   
 5.1 Press the left arrow button to view past results from the most recent to the oldest 
42 







Appendix D: HTA for Bayer® Contour® USB 
U.S. denotes usability score. 
Hierarchical Task Analysis U.S. 
Task Description Total 
1.0 Set up Meter   
 1.1 Plug the meter into a power source and wait until the battery is fully charged 
17 
 1.2 Turn on the meter by pressing and holding the Menu button until meter turns on 
 1.3 Perform the Initial Startup using Quickstart 
  1.3.1 Press the up or down scrolling buttons to select the desired language 
  1.3.2 Press the OK/middle button to confirm the language 
  1.3.3 
Press the up and/or down scrolling buttons to select the Quickstart op-
tion 
  1.3.4 Press the OK/middle button 
 1.4 Set Date  
  1.4.1 Press the up and/or down scrolling buttons to select the change option 
17 
  1.4.2 Press the OK/middle button to confirm the selection 
  1.4.3 
Press the up and/or down scrolling buttons to select the desired format 
of the date 
  1.4.4 Press the OK/middle button to confirm the desired date format.  
  1.4.5 Press the up and/or down scrolling buttons to select the correct year 
  1.4.6 Press the OK/middle button to confirm the year 
  1.4.7 Press the up and/or down scrolling buttons to select the correct month 
  1.4.8 Press the OK/middle button to confirm the month 
  1.4.9 Press the up and/or down scrolling buttons to select the correct day 
  1.4.10 Press the OK/middle button to confirm the day 
  1.4.11 Press the down scrolling button to select the Done option  
 1.5 Set Time  
  1.5.1 Press the Menu button to go back to the main menu 
17 
  1.5.2 Press the Setup button 
  1.5.3 Press the up and/or down scrolling buttons to select the Time option 
  1.5.4 Press the OK/middle button to confirm the selection 
  1.5.5 Press the up and/or down scrolling  buttons to select the desired time format 
  1.5.6 Press the up and/or down scrolling buttons to select the correct hour 
  1.5.7 Press the OK/middle button to confirm hour 
  1.5.8 Press the up and/or down scrolling buttons to select the correct minute 
  1.5.9  Press the OK/middle button to confirm minutes 






  1.5.11 Press the OK/middle button to confirm AM/PM 
  1.5.12 Press the down scrolling button to select the Done option  
 1.4 Perform the Initial Startup using Customize  
  1.4.1 Press the up or down scrolling buttons to select the desired language 
17 
  1.4.2 Press the OK/middle button to confirm the language 
  1.4.3 Press the up and/or down scrolling buttons to select the Customize op-tion 
  1.4.4 Set Date - Follow steps 1.3.6 
  1.4.5 Set Time - Follow step 1.3.6 
  1.4.6 Press the up and/or down scrolling buttons to select the Accept option on the Autolog screen 
  1.4.7 Press Ok/middle button to confirm the selection 
  1.4.8 Press the up and/or down scrolling buttons to select the change button in the current target screen  
  1.4.9 Press the OK/middle button to confirm selection  
  1.4.10 Press the up and/or down scrolling buttons to select the desired before meal low target number 
  1.4.11 Press the OK/middle button to confirm before meal low target number 
  1.4.12 Press the up and /or down scrolling buttons to select the desired before meal high target number 
  1.4.13 Press the OK/middle button to confirm before meal high target num-ber 
  1.4.14 Press the up and/or down scrolling buttons to select the desired after meal low target number  
  1.4.15 Press the OK/middle button to confirm after meal low target number 
  1.4.16 Press the up and /or down scrolling buttons to select the desired after meal high target number 
  1.4.17 Press the OK/middle button to confirm the desired after meal high tar-get number 
  1.4.18 Press the up and/or down scrolling buttons to select the Done option  
 1.5 Set Reminder  
  1.5.1 Press the up and/or down scrolling buttons to select the Setup Option from the main menu 
17 
  1.5.2 Press the up and/or down scrolling buttons to select the Reminder op-tion 
  1.5.3 Press the OK/middle button to confirm Reminder selection 
  1.5.4 Press the up and/or down scrolling buttons to select the Change option 
  1.5.5 Press the OK/middle button to confirm Change selection 
  1.5.6 Press the up and/or down scrolling buttons to the desired hours 
  1.5.7 Press the OK/middle button to confirm hour number 
  1.5.8 Press the up and/or down scrolling buttons to the desired minute num-ber 
  1.5.9 Press the OK/middle button to confirm minute number  
  1.5.10 Press the up and/or down scrolling buttons to select the done button 
2.0 Perform Control test  
 2.1 Gather the materials  






 2.3 Perform control solution test  
  2.3.1 Flip open the test strip container and get a test strip   
  2.3.2 Close the test strip container  
  2.3.2  Grab the meter and insert the test strip into the meter with the gray square end facing into the meter  
  2.3.3 Wait for the meter to be ready to test  
  2.3.4 Grab the desired level of control solution   
  2.3.5 Squeeze a small drop of the control solution onto a clean surface  
  2.3.6 Grab the meter and touch the tip of the test strip to the drop of control solution  
  2.3.7 Keep the tip of the test strip in the drop until meter beeps  
  2.3.8 Wait for the meter to display the result  
  2.3.9 Compare the control result obtained to the ranges provided on the test strip container.  
 2.4  Remove and discard test strip  
3.0 Prepare the Lancing Device   
 3.1 Gather the materials  
 3.2 Remove the end cap   
  3.2.1 Hold the lancing device on the grip indent side in one hand  
  3.2.2 Hold the end cap dial on the other hand  
  3.2.3 Snap off the end cap from top to bottom    
 3.3 Place the lancet into the lancing device   
  3.3.1 Hold the lancet and rotate the protective cap 1/4 of a turn  
  3.3.2 Push the lancet into the lancet holder  
  3.3.3 Twist off the protective cap on lancet  
 3.4 Place the end cap onto the lancing device  
4.0 Perform Test  
 4.1 Gather the materials  
 4.2 Wash hands  
 4.3 Get test strip   
 4.4 Insert test strip into the meter 
15 
 4.5 Wait for the meter to be ready to test 
 4.6 Prick finger  
  4.6.1 Hold the lancing device firmly against the side of the fingertip  
  4.6.2 Twist the dial at the end of the end cap to the desired puncture depth  
  4.6.3 Press the blue release button on the lancing device with your thumb   
  4.6.4 Gently squeeze the finger to promote blood flow  
 4.7 Touch the blood drop to the front edge of the test strip, where the sample tip is located  
 4.8 Press the up and/or down scrolling buttons to select the correct marker  
15  4.9 Wait for the meter to display the result 






 4.11 Remove and discard test strip   
 4.12 Remove the used lancet  
  4.12.1 Remove end cap  
  4.12.2 Place the protective cap of lancet on a flat surface with the Bayer logo face down  
  4.12.3 Push the lancet into the center of the protective cap  
  4.12.4 Point the device toward a container where the used lancet is to be dis-posed of  
  4.12.5 Press the blue release button and pull the blue setting handle past re-sistance on the lancing device  
  4.12.6 Place the end cap onto lancing device  
 4.13 Wash hands  
5.0 Create Reminder after Testing  
 5.1 Press the up and/or down scrolling buttons to select the Reminder option after test completion 26 
 5.2 Follow step 1.5 
6.0 Create Notes after Testing  
 6.1 Press the up and/or down scrolling buttons to select the Notes option after test completion 
26  6.2 Press the up and/or down scrolling buttons to select the correct choices 
 6.3 Press the OK/middle button to confirm the choice selection 
7.0 Change the settings of the meter and software GLUCOFACTS  
 7.1 Plug in meter into a USB port on a computer  
 7.2 Open the folder GLUCOFACTS deluxe  
 7.3 Open the Glucofacts executable jar file  
 7.4 Change Profile details  
  7.4.1 Click the Profile details tab in the window  
  7.4.2 Change the desired details  
  7.4.3 Press the Save Changes button on the bottom of the page.   
 7.5 Change the target, before meal, and after meal ranges   
  7.5.1 Click on the desired range option to be changed   
  7.5.2 Press the up and down arrow buttons to adjust to desired range  
  7.5.3 Click the update meter button on the bottom of the page   
 7.6 Change the meter settings   
  7.6.1 Click th meter settings tab  
  7.6.2 Change the date format, time format, sound, autolog and trend data to the desired format  
  7.6.3 Press the Update meter button on the bottom of the page  
 7.7 Change the Print Preferences   
  7.7.1 Press the Settings button on the top right corner of the window  
  7.7.2 Change the Printer settings as desired  
  7.7.3 Press the Save Changes button on the bottom of the page.   
 7.8 Print Reports  






 7.9 Save Report as a PDF  
  7.9.1 Press the Save as PDF button on the top right corner of the window  
8.0 View Results  
 8.1 Click the Reports tab of the window 
15 
 8.2 Press the Change data trend button and adjust to the desired data range 
 8.3 Press the trend subheading underneath the Report tab to view trend over the de-sired data range 
 8.4 Press the logbook subheading underneath the Report tab to view a total history of all reports 
 8.5 Press the Standard Day or Standard Week subheadings to view the results dur-ing that time period  

























Task 1: Turn on the glucometer 
 
 
1. Open the Button Door 
                   
2. Press the On/Off Button 
 
3. 
Confirm that the glucometer is 
on by stating out loud the date 
on the glucometer. 
 
 















Press the Memory Button. 




Read out loud the result value 
and the time the result was 
stored. 
     
3. Press the Down Button once to view the next stored result. 
 
4. 
Read out loud the result value 
and the time the result was 
stored. 




















Turn the meter over so the 




Open the meter by press-
ing up on the back edge 
latch and the pulling up on 
the base while positioning 
your thumb on the rear of 
the glucometer.        
3. 
Insert the test disc (with 
the bumpy side up), align-
ing the notches in the disc 
with the tabs on the glu-
cometer. 
                
4. Close the glucometer and snap it shut. 
 
5. 
Confirm that you complet-
ed the task by stating out 











Bayer Contour USB 
 
Task 1: Turn on the glucometer 
 
 
1. Press and hold the Menu But-ton for 3 seconds. 
  
2. 
After a welcome animation, 




Confirm that the meter is on 
by stating out loud the menu 













On the main menu, select 
“Logbook” by pressing the 
up Selection Button. The 
last result will be displayed.  
2. 
Read out loud the result 
value and the time the result 
was stored.  
3. 
Press the Bottom Selection 
Button once to view the next 
stored result.  
4. 
Read out loud the result 
value and the time the result 





















Hold the test strip with the 
gray end facing up. Insert the 
gray end into the test strip 
port on the meter 
 
2. 
The glucometer will display 
the Apply Blood screen. The 
meter is now ready for a 
blood test.  
3. 
Confirm that you completed 
the task by stating out loud 
















Press the On/Off Button. You 
will hear a beep sound when 
the meter is on. 
       
2. 
Confirm that the glucometer is 
on by stating out loud the date 
















Press the Left Button. The 
last result will be displayed 
and a beep sound is pro-
duced.             
2. 
Read out loud the result val-




Press the Left Button once to 
view the next stored result. 
You will hear a beep sound. 
            
4. 
Read out loud the result val-
























Hold the test strip with the gray 
and golden end facing up. In-
sert the golden end into the 
test strip port on the meter 
                
2. 
The glucometer will display the 
Apply Blood screen and you 
will hear a beep sound. The 




Confirm that you completed 

















Press the On/Off Button. You 
will hear a beep sound when 
the meter is on. 
           
2. 
Confirm that the glucometer is 
on by stating out loud the date 












Task 2: View Past Results 
 
 
1. Press the Left Button. The last result will be displayed. 
            
2. 
Read out loud the result value 
and the time the result was 
stored. 
 
3. Press the Left Button once to view the next stored result. 
            
4. 
Read out loud the result value 
























Hold the test strip with the blue 
and golden end facing up. In-
sert the golden end into the 
test strip port on the meter 
                
2. 
The glucometer will beep and 
display a code on the screen 
for 2 seconds. State out loud 










Appendix G: Statistical Analysis 
 
• Question 1: How easy or difficult was it for you to [a. see/b. use your hands] to 
perform Task 1 (power)? 
o Retinopathy 
Friedman Test 





Q1: Turn On Meter 
 
 
Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 5 4 3 4 
 2 3 3 4 4 
 3 3 5 5 4 
 4 4 5 5 3 
 5 3 4 5 5 
 6 5 4 4 4 
 7 5 5 5 5 
 8 2 3 3 1 
 9 5 5 4 4 
 
      Ranks 





Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 4 2.5 1 2.5 
 2 1.5 1.5 3.5 3.5 
 3 1 3.5 3.5 2 
 4 2 3.5 3.5 1 
 5 1 2 3.5 3.5 
 6 4 2 2 2 
 7 2.5 2.5 2.5 2.5 
 8 2 3.5 3.5 1 
 9 3.5 3.5 1.5 1.5 
 






Rank Totals Squared 462.25 600.25 600.25 380.25 
 Rank sum of squares 62.75 71.75 74.75 49.25 
 
      Data 
    Level of significance 0.05 
    
      Intermediate Calculations 
    Number of Blocks / subjects 9 
    Number of Treatments 4 
    A1 258.5 
    C1 225 
    T1 1.61194 
    T2 (adjusted - presence of 
ties) 0.507937 
    k1 (treatment dof) 3 
    k2 (dof) 24 
    Critical Value 3.008787 
    P-value 0.680543 









Q1: Turn On Meter 
 
 
Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 4 4 3 2 
 2 3 4 3 2 
 3 5 5 5 5 
 4 2 3 5 2 
 5 2 2 2 1 
 6 4 3 2 3 
 7 5 3 5 5 
 8 4 4 4 4 
 9 5 4 4 5 
 
      Ranks 










Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 3.5 3.5 2 1 
 2 2.5 4 2.5 1 
 3 2.5 2.5 2.5 2.5 
 4 1.5 3 4 1.5 
 5 3 3 3 1 
 6 4 2.5 1 2.5 
 7 3 1 3 3 
 8 2.5 2.5 2.5 2.5 
 9 3.5 1.5 1.5 3.5 
 
      Rank Totals 26 23.5 22 18.5 
 Rank Totals Squared 676 552.25 484 342.25 
 Rank sum of squares 79.5 68.25 60 45.25 
 
      Data 
    Level of significance 0.05 
    
      Intermediate Calculations 
    Number of Blocks / subjects 9 
    Number of Treatments 4 
    A1 253 
    C1 225 
    T1 3.160714 
    T2 (adjusted - presence of 
ties) 1.060674 
    k1 (treatment dof) 3 
    k2 (dof) 24 
    Critical Value 3.008787 
    P-value 0.384193 
    Accept the null hypothesis   
 
o Arthritis + Neuropathy 
Friedman Test 













Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 2 1 3 3 
 2 2 3 3 2 
 3 3 4 4 3 
 4 4 4 4 3 
 5 3 3 3 3 
 6 3 2 4 4 
 7 5 3 5 4 
 8 4 2 3 3 
 9 4 4 4 4 
 
      Ranks 





Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 2 1 3.5 3.5 
 2 1.5 3.5 3.5 1.5 
 3 1.5 3.5 3.5 1.5 
 4 3 3 3 1 
 5 2.5 2.5 2.5 2.5 
 6 2 1 3.5 3.5 
 7 3.5 1 3.5 2 
 8 4 1 2.5 2.5 
 9 2.5 2.5 2.5 2.5 
 
      Rank Totals 22.5 19 28 20.5 
 Rank Totals Squared 506.25 361 784 420.25 
 Rank sum of squares 62.25 50 89 52.75 
 
      Data 
    Level of significance 0.05 
    
      Intermediate Calculations 
    Number of Blocks / subjects 9 
    Number of Treatments 4 
    A1 254 
    C1 225 
    T1 4.810345 






T2 (adjusted - presence of 
ties) 1.734266 
    k1 (treatment dof) 3 
    k2 (dof) 24 
    Critical Value 3.008787 
    P-value 0.186733 
























Question 2: How easy or difficult was it for you to [a. see/b. use your hands] to 


























































Q2: Review Past Results 
 
 
Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 5 4 3 2 
 2 3 4 4 3 
 3 5 5 4 4 
 4 4 5 4 3 
 5 4 3 4 4 
 6 5 3 4 4 
 7 5 5 5 4 
 8 2 3 3 2 
 9 5 5 4 4 
 
      Ranks 
     Treatment 
 
 
Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 4 3 2 1 
 2 1.5 3.5 3.5 1.5 
 3 3.5 3.5 1.5 1.5 
 4 2.5 4 2.5 1 
 5 3 1 3 3 





7 3 3 3 1 
 8 1.5 3.5 3.5 1.5 
 9 3.5 3.5 1.5 1.5 
 
      Rank Totals 26.5 26 23 14.5 
 Rank Totals Squared 702.25 676 529 210.25 
 Rank sum of squares 85.25 85 63.5 27.25 
 
      Data 
    Level of significance 0.05 
    
      Intermediate Calculations 
    Number of Blocks / subjects 9 
    Number of Treatments 4 
    A1 261 
    C1 225 
    T1 7.708333 
    T2 (adjusted - presence of 
ties) 3.196544 
    k1 (treatment dof) 3 
    k2 (dof) 24 
    Critical Value 3.008787 
    P-value 0.041519 
    
Reject the null hypothesis Multiple Comparison below is meaning-ful  
 
Multiple Comparison 
Critical Value 9.065113019 
Breeze2 - Aviva 0.5 no statistical difference 
Breeze2 - Nano 3.5 no statistical difference 
Breeze2 - USB 12 Breeze2 is statistically greater than USB 
Aviva - Nano 3 no statistical difference 
Aviva - USB 11.5 Aviva is statistically greater than USB 














Q2: Review Past Results 
 
 
Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 4 4 3 2 
 2 3 3 2 1 
 3 5 5 4 4 
 4 4 3 4 2 
 5 2 2 1 2 
 6 5 4 2 3 
 7 5 5 3 5 
 8 4 4 3 4 
 9 5 5 3 5 
 
      Ranks 





Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 3.5 3.5 2 1 
 2 3.5 3.5 2 1 
 3 3.5 3.5 1.5 1.5 
 4 3.5 2 3.5 1 
 5 3 3 1 3 
 6 4 3 1 2 
 7 3 3 1 3 
 8 3 3 1 3 
 9 3 3 1 3 
 
      Rank Totals 30 27.5 14 18.5 
 Rank Totals Squared 900 756.25 196 342.25 
 Rank sum of squares 101 85.75 27.5 45.25 
 
      Data 
    Level of significance 0.05 
    
      Intermediate Calculations 
    Number of Blocks / subjects 9 
    Number of Treatments 4 
    A1 259.5 







    T1 14.73913 
    T2 (adjusted - presence of 
ties) 9.617021 
    k1 (treatment dof) 3 
    k2 (dof) 24 
    Critical Value 3.008787 
    P-value 0.000236 
    
Reject the null hypothesis Multiple Comparison below is meaning-ful  
 
Multiple Comparison 
Critical Value 7.074687834 
Breeze2 - Aviva 2.5 no statistical difference 
Breeze2 - Nano 16 Breeze2 is statistically greater than Nano 
Breeze2 - USB 11.5 Breeze2 is statistically greater than USB 
Aviva - Nano 13.5 Aviva is statistically greater than Nano 
Aviva - USB 9 Aviva is statistically greater than USB 
Nano - USB -4.5 no statistical difference 
 
o Arthritis + Neuropathy 
Friedman Test 





Q2: Review Past Results 
 
 
Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 3 4 3 1 
 2 2 4 2 2 
 3 3 5 4 3 
 4 3 4 3 4 
 5 2 3 2 2 
 6 3 5 3 3 
 7 5 5 4 4 
 8 4 4 4 2 
 9 3 5 4 3 
 
      Ranks 










Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 2.5 4 2.5 1 
 2 2 4 2 2 
 3 1.5 4 3 1.5 
 4 1.5 3.5 1.5 3.5 
 5 2 4 2 2 
 6 2 4 2 2 
 7 3.5 3.5 1.5 1.5 
 8 3 3 3 1 
 9 1.5 4 3 1.5 
 
      Rank Totals 19.5 34 20.5 16 
 Rank Totals Squared 380.25 1156 420.25 256 
 Rank sum of squares 46.25 129.5 49.75 33 
 
      Data 
    Level of significance 0.05 
    
      Intermediate Calculations 
    Number of Blocks / subjects 9 
    Number of Treatments 4 
    A1 258.5 
    C1 225 
    T1 16.79104 
    T2 (adjusted - presence of 
ties) 13.15789 
    k1 (treatment dof) 3 
    k2 (dof) 24 
    Critical Value 3.008787 
    P-value 2.78E-05 
    
Reject the null hypothesis Multiple Comparison below is meaning-ful  
 
Multiple Comparison 
Critical Value 6.361362597 
Breeze2 - Aviva -14.5 Aviva is statistically greater than Breeze2 






Breeze2 - USB 3.5 no statistical difference 
Aviva - Nano 13.5 Aviva is statistically greater than Nano 
Aviva - USB 18 Aviva is statistically greater than USB 
Nano - USB 4.5 no statistical difference 
 
• Question 3: How easy or difficult was it for you to [a. see/b. use your hands] to 



































Q3: Insert Test Strip 
 
 
Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 4 4 3 4 
 2 4 5 2 4 
 3 2 5 5 4 
 4 2 5 4 4 
 5 3 3 4 4 
 6 5 4 3 4 
 7 5 4 3 5 
 8 1 3 2 1 
 9 5 5 4 4 
 
      Ranks 





Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 3 3 1 3 
 2 2.5 4 1 2.5 
 3 1 3.5 3.5 2 
 4 1 4 2.5 2.5 
 5 1.5 1.5 3.5 3.5 
 6 4 2.5 1 2.5 
 7 3.5 2 1 3.5 
 8 1.5 4 3 1.5 







      Rank Totals 21.5 28 18 22.5 
 Rank Totals Squared 462.25 784 324 506.25 
 Rank sum of squares 62.25 94 46 60.75 
 
      Data 
    Level of significance 0.05 
    
      Intermediate Calculations 
    Number of Blocks / subjects 9 
    Number of Treatments 4 
    A1 263 
    C1 225 
    T1 4.065789 
    T2 (adjusted - presence of 
ties) 1.418244 
    k1 (treatment dof) 3 
    k2 (dof) 24 
    Critical Value 3.008787 
    P-value 0.261888 









Q3: Insert Test Strip 
 
 
Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 3 4 2 4 
 2 2 4 1 2 
 3 5 5 5 5 
 4 1 3 5 3 
 5 1 1 2 1 
 6 4 3 3 3 
 7 4 4 5 3 
 8 4 4 4 3 







      Ranks 





Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 2 3.5 1 3.5 
 2 2.5 4 1 2.5 
 3 2.5 2.5 2.5 2.5 
 4 1 2.5 4 2.5 
 5 2 2 4 2 
 6 4 2 2 2 
 7 2.5 2.5 4 1 
 8 3 3 3 1 
 9 2.5 2.5 1 4 
 
      Rank Totals 22 24.5 22.5 21 
 Rank Totals Squared 484 600.25 506.25 441 
 Rank sum of squares 59 70.25 70.25 57 
 
      Data 
    Level of significance 0.05 
    
      Intermediate Calculations 
    Number of Blocks / subjects 9 
    Number of Treatments 4 
    A1 256.5 
    C1 225 
    T1 0.619048 
    T2 (adjusted - presence of 
ties) 0.187726 
    k1 (treatment dof) 3 
    k2 (dof) 24 
    Critical Value 3.008787 
    P-value 0.903706 
    Accept the null hypothesis   
 












Q3: Insert Test Strip 
 
 
Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 2 2 2 2 
 2 2 3 2 3 
 3 3 4 3 2 
 4 1 4 3 3 
 5 3 2 2 2 
 6 2 3 3 3 
 7 5 4 4 3 
 8 3 2 1 2 
 9 3 4 4 4 
 
      Ranks 





Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 2.5 2.5 2.5 2.5 
 2 1.5 3.5 1.5 3.5 
 3 2.5 4 2.5 1 
 4 1 4 2.5 2.5 
 5 4 2 2 2 
 6 1 3 3 3 
 7 4 2.5 2.5 1 
 8 4 2.5 1 2.5 
 9 1 3 3 3 
 
      Rank Totals 21.5 27 20.5 21 
 Rank Totals Squared 462.25 729 420.25 441 
 Rank sum of squares 65.75 85 50.25 55 
 
      Data 
    Level of significance 0.05 
    
      Intermediate Calculations 
    Number of Blocks / subjects 9 
    Number of Treatments 4 







    C1 225 
    T1 2.66129 
    T2 (adjusted - presence of 
ties) 0.874751 
    k1 (treatment dof) 3 
    k2 (dof) 24 
    Critical Value 3.008787 
    P-value 0.467926 
    Accept the null hypothesis   
 
 































Q4: Ease of Text Reading 
 
 
Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 5 4 3 2 
 2 3 4 4 3 
 3 5 4 4 4 
 4 4 5 5 4 
 5 4 4 4 5 
 6 5 3 4 4 
 7 5 4 5 4 
 8 3 3 3 2 
 9 5 5 3 4 
 
      Ranks 





Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 4 3 2 1 
 2 1.5 3.5 3.5 1.5 
 3 4 2 2 2 
 4 1.5 3.5 3.5 1.5 






6 4 1 2.5 2.5 
 7 3.5 1.5 3.5 1.5 
 8 3 3 3 1 
 9 3.5 3.5 1 2 
 
      Rank Totals 27 23 23 17 
 Rank Totals Squared 729 529 529 289 
 Rank sum of squares 90 66 65 39 
 
      Data 
    Level of significance 0.05 
    
      Intermediate Calculations 
    Number of Blocks / subjects 9 
    Number of Treatments 4 
    A1 260 
    C1 225 
    T1 4.371429 
    T2 (adjusted - presence of 
ties) 1.545455 
    k1 (treatment dof) 3 
    k2 (dof) 24 
    Critical Value 3.008787 
    P-value 0.228491 









Q4: Ease of Text Reading 
 
 
Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 4 4 2 3 
 2 2 2 3 2 
 3 5 5 5 4 
 4 4 3 5 2 







6 4 3 2 3 
 7 4 5 5 5 
 8 4 4 3 3 
 9 5 4 3 4 
 
      Ranks 





Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 3.5 3.5 1 2 
 2 2 2 4 2 
 3 3 3 3 1 
 4 3 2 4 1 
 5 4 2 2 2 
 6 4 2.5 1 2.5 
 7 1 3 3 3 
 8 3.5 3.5 1.5 1.5 
 9 4 2.5 1 2.5 
 
      Rank Totals 28 24 20.5 17.5 
 Rank Totals Squared 784 576 420.25 306.25 
 Rank sum of squares 95.5 67 59.25 37.75 
 
      Data 
    Level of significance 0.05 
    
      Intermediate Calculations 
    Number of Blocks / subjects 9 
    Number of Treatments 4 
    A1 259.5 
    C1 225 
    T1 5.347826 
    T2 (adjusted - presence of 
ties) 1.975904 
    k1 (treatment dof) 3 
    k2 (dof) 24 
    Critical Value 3.008787 
    P-value 0.144494 
















Q5: Text Satisfaction 
 
 
Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 4 3 3 3 
 2 3 4 3 4 
 3 4 4 4 4 
 4 4 5 4 2 
 5 4 5 3 4 
 6 5 3 4 3 
 7 5 4 5 5 
 8 2 4 3 2 
 9 5 4 3 4 
 
      Ranks 





Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 4 2 2 2 
 2 1.5 3.5 1.5 3.5 
 3 2.5 2.5 2.5 2.5 
 4 2.5 4 2.5 1 
 5 2.5 4 1 2.5 
 6 4 1.5 3 1.5 
 7 3 1 3 3 
 8 1.5 4 3 1.5 
 9 4 2.5 1 2.5 
 
      Rank Totals 25.5 25 19.5 20 
 Rank Totals Squared 650.25 625 380.25 400 







      Data 
    Level of significance 0.05 
    
      Intermediate Calculations 
    Number of Blocks / subjects 9 
    Number of Treatments 4 
    A1 257.5 
    C1 225 
    T1 2.815385 
    T2 (adjusted - presence of 
ties) 0.931298 
    k1 (treatment dof) 3 
    k2 (dof) 24 
    Critical Value 3.008787 
    P-value 0.440822 









Q5: Text Satisfaction 
 
 
Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 3 4 3 3 
 2 2 3 3 3 
 3 4 5 4 4 
 4 3 4 4 2 
 5 3 2 1 2 
 6 4 3 3 3 
 7 5 5 5 5 
 8 4 4 3 2 
 9 5 4 2 4 
 
      Ranks 












Blocks/Subjects 1 2 3 4 
 1 2 4 2 2 
 2 1 3 3 3 
 3 2 4 2 2 
 4 2 3.5 3.5 1 
 5 4 2.5 1 2.5 
 6 4 2 2 2 
 7 2.5 2.5 2.5 2.5 
 8 3.5 3.5 2 1 
 9 4 2.5 1 2.5 
 
      Rank Totals 25 27.5 19 18.5 
 Rank Totals Squared 625 756.25 361 342.25 
 Rank sum of squares 79.5 88.25 45.5 41.75 
 
      Data 
    Level of significance 0.05 
    
      Intermediate Calculations 
    Number of Blocks / subjects 9 
    Number of Treatments 4 
    A1 255 
    C1 225 
    T1 5.95 
    T2 (adjusted - presence of ties) 2.261283 
    k1 (treatment dof) 3 
    k2 (dof) 24 
    Critical Value 3.008787 
    P-value 0.107114 
    Accept the null hypothesis   
 
 
• Question 6.a: How would you rate your overall satisfaction with the shape and 


















Q6: Screen Satisfaction 
 
 
Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 4 4 3 2 
 2 3 4 3 4 
 3 4 5 4 4 
 4 5 4 5 3 
 5 5 4 3 3 
 6 5 3 3 3 
 7 5 5 5 5 
 8 2 4 3 2 
 9 5 5 3 4 
 
      Ranks 





Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 3.5 3.5 2 1 
 2 1.5 3.5 1.5 3.5 
 3 2 4 2 2 
 4 3.5 2 3.5 1 
 5 4 3 1.5 1.5 
 6 4 2 2 2 
 7 2.5 2.5 2.5 2.5 
 8 1.5 4 3 1.5 
 9 3.5 3.5 1 2 
 
      Rank Totals 26 28 19 17 
 Rank Totals Squared 676 784 361 289 
 Rank sum of squares 83.5 92 45 37 
 
      Data 
    Level of significance 0.05 
    
      Intermediate Calculations 
    Number of Blocks / subjects 9 
    Number of Treatments 4 
    A1 257.5 







    T1 7.846154 
    T2 (adjusted - presence of 
ties) 3.277108 
    k1 (treatment dof) 3 
    k2 (dof) 24 
    Critical Value 3.008787 
    P-value 0.038363 
    
Reject the null hypothesis Multiple Comparison below is meaning-ful  
 
Multiple Comparison 
Critical Value 8.582360952 
Breeze2 - Aviva -2 no statistical difference 
Breeze2 - Nano 7 no statistical difference 
Breeze2 - USB 9 Breeze2 is statistically greater than USB 
Aviva - Nano 9 Aviva is statistically greater than Nano 
Aviva - USB 11 Aviva is statistically greater than USB 









Q6: Screen Satisfaction 
 
 
Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 4 4 3 2 
 2 3 3 3 4 
 3 4 5 4 4 
 4 4 4 4 2 
 5 2 2 2 1 
 6 4 4 3 2 
 7 5 5 5 5 
 8 3 4 4 1 
 9 5 4 3 5 
 
      Ranks 










Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 3.5 3.5 2 1 
 2 2 2 2 4 
 3 2 4 2 2 
 4 3 3 3 1 
 5 3 3 3 1 
 6 3.5 3.5 2 1 
 7 2.5 2.5 2.5 2.5 
 8 2 3.5 3.5 1 
 9 3.5 2 1 3.5 
 
      Rank Totals 25 27 21 17 
 Rank Totals Squared 625 729 441 289 
 Rank sum of squares 73 85 53.5 43.5 
 
      Data 
    Level of significance 0.05 
    
      Intermediate Calculations 
    Number of Blocks / subjects 9 
    Number of Treatments 4 
    A1 255 
    C1 225 
    T1 5.9 
    T2 (adjusted - presence of 
ties) 2.236967 
    k1 (treatment dof) 3 
    k2 (dof) 24 
    Critical Value 3.008787 
    P-value 0.109863 










• Question 4.b: How easy or difficult was it for you to feel the buttons? 
o Arthritis + Neuropathy 
Friedman Test 





Q4b: Ease of Button Feeling 
 
 
Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 3 2 1 4 
 2 2 2 1 1 
 3 2 2 3 2 
 4 2 4 2 2 
 5 2 3 1 2 
 6 2 3 2 2 
 7 5 3 4 3 
 8 3 2 2 2 
 9 2 4 3 3 
 
      Ranks 





Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 3 2 1 4 
 2 3.5 3.5 1.5 1.5 
 3 2 2 4 2 
 4 2 4 2 2 
 5 2.5 4 1 2.5 
 6 2 4 2 2 
 7 4 1.5 3 1.5 
 8 4 2 2 2 
 9 1 4 2.5 2.5 
 
      Rank Totals 24 27 19 20 
 Rank Totals Squared 576 729 361 400 
 Rank sum of squares 72.5 90.5 47.5 49 
 
      Data 
    Level of significance 0.05 
    






    Number of Blocks / subjects 9 
    Number of Treatments 4 
    A1 259.5 
    C1 225 
    T1 3.565217 
    T2 (adjusted - presence of 
ties) 1.217069 
    k1 (treatment dof) 3 
    k2 (dof) 24 
    Critical Value 3.008787 
    P-value 0.324996 
    Accept the null hypothesis   
 
 





















Arthritis + Neuropathy 
Friedman Test 





Q5b: Ease od Buttons Pressing 
 
 
Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 3 2 4 2 
 2 3 4 3 1 
 3 3 4 4 3 
 4 2 5 2 3 
 5 1 3 2 1 
 6 3 3 3 3 
 7 5 3 4 3 
 8 4 3 3 3 
 9 3 5 3 4 
 
      Ranks 





Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 






2 2.5 4 2.5 1 
 3 1.5 3.5 3.5 1.5 
 4 1.5 4 1.5 3 
 5 1.5 4 3 1.5 
 6 2.5 2.5 2.5 2.5 
 7 4 1.5 3 1.5 
 8 4 2 2 2 
 9 1.5 4 1.5 3 
 
      Rank Totals 22 27 23.5 17.5 
 Rank Totals Squared 484 729 552.25 306.25 
 Rank sum of squares 62.5 91 67.25 38.25 
 
      Data 
    Level of significance 0.05 
    
      Intermediate Calculations 
    Number of Blocks / subjects 9 
    Number of Treatments 4 
    A1 259 
    C1 225 
    T1 4.102941 
    T2 (adjusted - presence of ties) 1.433526 
    k1 (treatment dof) 3 
    k2 (dof) 24 
    Critical Value 3.008787 
    P-value 0.257628 
    Accept the null hypothesis   
 
 
















Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 3 4 4 2 
 2 3 4 4 2 
 3 5 5 4 3 
 4 4 5 4 2 
 5 3 4 4 3 
 6 4 4 4 4 
 7 5 4 4 3 
 8 1 4 3 1 
 9 3 5 2 3 
 
      Ranks 





Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 2 3.5 3.5 1 
 2 2 3.5 3.5 1 
 3 3.5 3.5 2 1 
 4 2.5 4 2.5 1 
 5 1.5 3.5 3.5 1.5 
 6 2.5 2.5 2.5 2.5 
 7 4 2.5 2.5 1 
 8 1.5 4 3 1.5 
 9 2.5 4 1 2.5 
 
      Rank Totals 22 31 24 13 
 Rank Totals Squared 484 961 576 169 
 Rank sum of squares 59.5 109.5 69.5 22 
 
      Data 
    Level of significance 0.05 
    
      Intermediate Calculations 
    Number of Blocks / subjects 9 
    Number of Treatments 4 
    A1 260.5 
    C1 225 
    T1 13.94366 






T2 (adjusted - presence of ties) 8.543689 
    k1 (treatment dof) 3 
    k2 (dof) 24 
    Critical Value 3.008787 
    P-value 0.00049 
    
Reject the null hypothesis Multiple Comparison below is meaning-ful  
 
Multiple Comparison 
Critical Value 7.40562927 
Breeze2 - Aviva -9 Aviva is statistically greater than Breeze2 
Breeze2 - Nano -2 no statistical difference 
Breeze2 - USB 9 Breeze2 is statistically greater than USB 
Aviva - Nano 7 no statistical difference 
Aviva - USB 18 Aviva is statistically greater than USB 









Q7: Button Satisfaction 
 
 
Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 3 5 2 2 
 2 2 4 2 1 
 3 5 5 4 4 
 4 2 5 4 3 
 5 1 3 1 2 
 6 4 4 3 2 
 7 4 3 4 4 
 8 3 5 3 2 
 9 3 5 2 4 
 
      Ranks 





Breeze2 Aviva Nano USB 







1 3 4 1.5 1.5 
 2 2.5 4 2.5 1 
 3 3.5 3.5 1.5 1.5 
 4 1 4 3 2 
 5 1.5 4 1.5 3 
 6 3.5 3.5 2 1 
 7 3 1 3 3 
 8 2.5 4 2.5 1 
 9 2 4 1 3 
 
      Rank Totals 22.5 32 18.5 17 
 Rank Totals Squared 506.25 1024 342.25 289 
 Rank sum of squares 62.25 121.5 42.25 38.5 
 
      Data 
    Level of significance 0.05 
    
      Intermediate Calculations 
    Number of Blocks / subjects 9 
    Number of Treatments 4 
    A1 264.5 
    C1 225 
    T1 10.36709 
    T2 (adjusted - presence of ties) 4.986301 
    k1 (treatment dof) 3 
    k2 (dof) 24 
    Critical Value 3.008787 
    P-value 0.007896 
    
Reject the null hypothesis Multiple Comparison below is meaning-ful  
 
Multiple Comparison 
Critical Value 8.81697852 
Breeze2 - Aviva -9.5 Aviva is statistically greater than Breeze2 
Breeze2 - Nano 4 no statistical difference 
Breeze2 - USB 5.5 no statistical difference 
Aviva - Nano 13.5 Aviva is statistically greater than Nano 






Nano - USB 1.5 no statistical difference 
 
o Arthritis + Neuropathy 
Friedman Test 





Q7: Button Satisfaction 
 
 
Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 3 2 3 1 
 2 2 4 2 1 
 3 3 4 3 4 
 4 2 4 3 2 
 5 2 3 1 1 
 6 2 4 3 3 
 7 5 3 4 3 
 8 2 3 1 2 
 9 2 4 2 3 
 
      Ranks 





Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 3.5 2 3.5 1 
 2 2.5 4 2.5 1 
 3 1.5 3.5 1.5 3.5 
 4 1.5 4 3 1.5 
 5 3 4 1.5 1.5 
 6 1 4 2.5 2.5 
 7 4 1.5 3 1.5 
 8 2.5 4 1 2.5 
 9 1.5 4 1.5 3 
 
      Rank Totals 21 31 20 18 
 Rank Totals Squared 441 961 400 324 
 Rank sum of squares 57.5 114.5 50.5 42.5 
 
      Data 
    Level of significance 0.05 





      Intermediate Calculations 
    Number of Blocks / subjects 9 
    Number of Treatments 4 
    A1 265 
    C1 225 
    T1 7.575 
    T2 (adjusted - presence of 
ties) 3.119691 
    k1 (treatment dof) 3 
    k2 (dof) 24 
    Critical Value 3.008787 
    P-value 0.044789 
    
Reject the null hypothesis Multiple Comparison below is meaning-ful  
 
Multiple Comparison 
Critical Value 9.588432326 
Breeze2 - Aviva -10 Aviva is statistically greater than Breeze2 
Breeze2 - Nano 1 no statistical difference 
Breeze2 - USB 3 no statistical difference 
Aviva - Nano 11 Aviva is statistically greater than Nano 
Aviva - USB 13 Aviva is statistically greater than USB 
Nano - USB 2 no statistical difference 
 
 
• Question 6.b: How easy or difficult was it for you to grasp the meter? 
o Arthritis + Neuropathy 
Friedman Test 





Q6b: Ease of Meter Grabbing 
 
 
Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 2 3 2 2 
 2 4 4 2 2 
 3 4 4 3 3 






5 4 4 2 2 
 6 4 4 4 4 
 7 5 4 5 5 
 8 5 5 4 5 
 9 4 3 2 5 
 
      Ranks 





Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 2 4 2 2 
 2 3.5 3.5 1.5 1.5 
 3 3.5 3.5 1.5 1.5 
 4 3 2 1 4 
 5 3.5 3.5 1.5 1.5 
 6 2.5 2.5 2.5 2.5 
 7 3 1 3 3 
 8 3 3 1 3 
 9 3 2 1 4 
 
      Rank Totals 27 25 15 23 
 Rank Totals Squared 729 625 225 529 
 Rank sum of squares 83 77 29 67 
 
      Data 
    Level of significance 0.05 
    
      Intermediate Calculations 
    Number of Blocks / subjects 9 
    Number of Treatments 4 
    A1 256 
    C1 225 
    T1 8.032258 
    T2 (adjusted - presence of 
ties) 3.387755 
    k1 (treatment dof) 3 
    k2 (dof) 24 
    Critical Value 3.008787 
    P-value 0.034439 










Critical Value 8.341146731 
Breeze2 - Aviva 2 no statistical difference 
Breeze2 - Nano 12 Breeze2 is statistically greater than Nano 
Breeze2 - USB 4 no statistical difference 
Aviva - Nano 10 Aviva is statistically greater than Nano 
Aviva - USB 2 no statistical difference 
Nano - USB -8 no statistical difference 
 























Arthritis + Neuropathy 
Friedman Test 





Q8b: Meter Weight Satisfaction 
 
 
Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 5 4 3 4 
 2 5 5 5 5 
 3 4 5 5 5 
 4 3 4 4 5 
 5 4 4 4 4 
 6 3 4 5 4 
 7 5 5 5 4 
 8 3 4 5 5 
 9 5 5 5 5 
 
      Ranks 





Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 4 2.5 1 2.5 






3 1 3 3 3 
 4 1 2.5 2.5 4 
 5 2.5 2.5 2.5 2.5 
 6 1 2.5 4 2.5 
 7 3 3 3 1 
 8 1 2 3.5 3.5 
 9 2.5 2.5 2.5 2.5 
 
      Rank Totals 18.5 23 24.5 24 
 Rank Totals Squared 342.25 529 600.25 576 
 Rank sum of squares 47.75 59.5 72.25 69.5 
 
      Data 
    Level of significance 0.05 
    
      Intermediate Calculations 
    Number of Blocks / subjects 9 
    Number of Treatments 4 
    A1 249 
    C1 225 
    T1 2.8125 
    T2 (adjusted - presence of 
ties) 0.930233 
    k1 (treatment dof) 3 
    k2 (dof) 24 
    Critical Value 3.008787 
    P-value 0.441319 
    Accept the null hypothesis   
 
 









Arthritis + Neuropathy 
Friedman Test 












Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 3 4 3 3 
 2 3 4 2 2 
 3 4 4 3 4 
 4 4 3 2 5 
 5 5 4 3 3 
 6 4 4 4 4 
 7 5 5 5 5 
 8 3 5 4 3 
 9 5 4 3 5 
 
      Ranks 





Breeze2 Aviva Nano USB 
 Blocks/Subjects 1 2 3 4 
 1 2 4 2 2 
 2 3 4 1.5 1.5 
 3 3 3 1 3 
 4 3 2 1 4 
 5 4 3 1.5 1.5 
 6 2.5 2.5 2.5 2.5 
 7 2.5 2.5 2.5 2.5 
 8 1.5 4 3 1.5 
 9 3.5 2 1 3.5 
 
      Rank Totals 25 27 16 22 
 Rank Totals Squared 625 729 256 484 
 Rank sum of squares 74 86.5 33 60.5 
 
      Data 
    Level of significance 0.05 
    
      Intermediate Calculations 
    Number of Blocks / subjects 9 
    Number of Treatments 4 
    A1 254 
    C1 225 
    T1 7.137931 






T2 (adjusted - presence of 
ties) 2.875 
    k1 (treatment dof) 3 
    k2 (dof) 24 
    Critical Value 3.008787 
    P-value 0.057159 
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